Naar www.iknl.nl
- Urologie > Prostaatcarcinoom
Notificatie richtlijn E-mail richtlijn Naar startpagina oncoline
----------

Laatst gewijzigd: 2016-09-15, Versie: 2.1, Verantwoording: Nederlandse Vereniging voor Urologie, Type: Landelijke richtlijn

Referentielijst

1 - Aapro M (2008)
Aapro M, Abrahamsson P, Body J, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008 Mar;19(3):420-32. [link]
 
2 - Abrahamsson P (2009)
Abrahamsson P, Artibani W, Chapple C, et al. Wirth M. European Association of Urology position statement on screening for prostate cancer. Eur Urol. 2009;56(2):270-71. [link]
 
3 - Adami S (1989)
Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 1989;116:67-72. [link]
 
4 - Adkison J (2012)
Adkison J, McHaffie D, Bentzen S, et al. Phase I Trial of Pelvic Nodal Dose Escalation with Hypofractionated IMRT for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. [link]
 
5 - Ahmed H (2012)
Ahmed H, Cathcart P, McCartan N, et al. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer 2012;118(17):4148-55. [link]
 
6 - Alemozaffar M (2011)
Alemozaffar M, Regan M, Cooperberg M, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306(11):1205-14. [link]
 
7 - Alicikus Z (2011)
Alicikus Z, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011;117(7):1429-37. [link]
 
8 - Allaf M (2004)
Allaf M, Palapattu G, Trock B, et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004 Nov;172(5 Pt 1):1840-4. [link]
 
9 - Allen D (2004)
Allen D, Hindley R, Clovis S, et al. Does body-coil magnetic-resonance imaging have a role in the preoperative staging of patients with clinically localized prostate cancer? BJU Int. 2004;94(4):534-8.
 
10 - Allen J (2011)
Allen J, Berry D. Multi-media support for informed/shared decision-making before and after a cancer diagnosis. Seminars in Onc Nurs 2011;27:192-202. [link]
 
11 - Al-Mamgani A (2009)
Al-Mamgani A, Heemsbergen W, Peeters S, et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73(3):685-91. [link]
 
12 - Al-Mamgani A (2011)
Al-Mamgani A, van Putten W, van der Wielen G et al. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int J Radiat Oncol Biol Phys 2011;79(4):1004-12. [link]
 
13 - Andriole G (2009)
Andriole G, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-9. [link]
 
14 - Andriole G (2012)
Andriole G, et al. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. J Natl Cancer Inst 2012;104(2):125-32. [link]
 
15 - Arcangeli G (2010)
Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 2010;78(1):11-8. [link]
 
16 - Arsov C (2012)
Arsov C, Quentin M, Rabenalt R, et al. Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - A pilot study. Anticancer Res 2012;32(3):1087-92. [link]
 
17 - Asbell S (1988)
Asbell S, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988;15:1307-16. [link]
 
18 - Asimakopoulos A (2011)
Asimakopoulos A, Pereira Fraga C, et al. Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. J Sex Med 2011;8(5):1503-12. [link]
 
19 - Augustin H (2013)
Augustin H, Mayrhofer K, Pummer K, et al. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate 2013;73(2):203-10. [link]
 
20 - Bader P (2003)
Bader P, Burkhard F, Markwalder R, et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169(3):849-54. [link]
 
21 - Bahn D (2003)
Bahn D, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer 2003;2:111-4. [link]
 
22 - Barr R (2012)
Barr R, Memo R, Schaub C. Shear wave ultrasound elastography of the prostate: initial results. Ultrasound Q 2012;28(1):13-20. [link]
 
23 - Bauer J (1996)
Bauer J, Sesterhenn I, Mostofi F, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996;156(4):1511-6. [link]
 
24 - Bauman G (2012)
Bauman G, et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012;15:45-55. [link]
 
25 - Beckendorf V (2011)
Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056-63. [link]
 
26 - Beheshti M (2010)
Beheshti M, Imamovic L, Broinger G, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254(3):925-33. [link]
 
27 - Beheshti M (2010)
Beheshti M, Imamovic L, Broinger G, et al. 18F choline PET0/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: A prospective study of 130 patients. Radiology 2010;254(3):925-33. [link]
 
28 - Beissner R (2002)
Beissner R, Stricker J, Speights V, et al. Frozen section diagnosis of metastatic prostate adenocarcinoma in pelvic lymphadenectomy compared with nomogram prediction of metastasis. Urology 2002;59(5):721-5. [link]
 
29 - Berkovic P (2013)
Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013;11(1):27-32. [link]
 
30 - Berney D (2011)
Berney D, Wheeler T, Grignon D, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol 2011;24(1):39-47. [link]
 
31 - Berryhill R (2008)
Berryhill R, Jhaveri J, Yadav R, et al. Robotic prostatectomy: a review of outcomes compared with laparoscopic and open approaches. Urology 2008;72(1):15-23. [link]
 
32 - Billis A (2005)
Billis A, Guimaraes M, Freitas L, et al. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008;180(2):548-52. [link]
 
33 - Blanker M (2003)
Blanker M, Groeneveld F, Thomas S, et al. Prostate cancer detection in older men with and without lower urinary tract symptoms: a population-based study. J Am Geriatr Soc 2003;51(7):1041-2. [link]
 
34 - Bolla M (2012)
Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018-27. [link]
 
35 - Boormans J (2008)
Boormans J, Wildhagen M, Bangma C, et al. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer. BJU Int 2008;102(11):1589-93. [link]
 
36 - Borden L Jr (2007)
Borden L Jr, Wright J, Kim J, et al. An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int 2007;99(3):559-63. [link]
 
37 - Börgermann C (2009)
Börgermann C. The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful! World J Urol 2009;27(5):581-5. [link]
 
38 - Botchorishvili G (2009)
Botchorishvili G, Matikainen M, Lilja H. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol 2009;19(3):221-6. [link]
 
39 - Braeckman J (2008)
Braeckman J, Autier P, Garbar C, et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 2008;101(3):293-8. [link]
 
40 - Brajtbord J (2011)
Brajtbord J, Lavery H, Nabizada-Pace F, et al. Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer. BJU Int 2011;107(9):1419-24. [link]
 
41 - Brawley O (2010)
Brawley O, Gansler T. Introducing the 2010 American Cancer Society Prostate Cancer Screening Guideline. CA Cancer J Clin 2010;60(2):68-69. [link]
 
42 - Breeuwsma A (2010)
Breeuwsma A, Pruim J, Bergh van den A, et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 20101;77(1):160-4. [link]
 
43 - Brenner D (2002)
Brenner D, Martinez A, Edmundson G, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52(1):6-13. [link]
 
44 - Briganti A (2009)
Briganti A, Karnes J, Da Pozzo L, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55(2):261-70. [link]
 
45 - Briganti A (2009)
Briganti A, Blute M, Eastham J, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55(6):1251-65. [link]
 
46 - Briganti A (2007)
Briganti A, Chun F, Salonia A, et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 2007;69(1):147-51. [link]
 
47 - Briganti A (2010)
Briganti A, Gallina A, Suardi N, et al. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. J Sex Med 2010;7(7):2521-31. [link]
 
48 - Brimo F (2010)
Brimo F, Partin A, Epstein J. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology 2010;76(5):1206-9. [link]
 
49 - Brown J (2009)
Brown J, Rodin D, Harisinghani M, et al. Impact of preoperative endorectal MRI stage classification on neurovascular bundle sparing aggressiveness and the radical prostatectomy positive margin rate. Urol Oncol 2009;27(2):174-9. [link]
 
50 - Bruner D (2003)
Bruner D, Moore D, Parlanti A, et al. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003;107(5):797-803. [link]
 
51 - Budaus L (2012)
Budaus L, Bolla M, Bossi A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012;61(1):112-27. [link]
 
52 - Budiharto T (2011)
Budiharto T, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011;60:125-30. [link]
 
53 - Bul M (2011)
Bul M, van Leeuwen P, Zhu X, et al. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol 2011;59(4):498-505.http://www.ncbi.nlm.nih.gov/pubmed/?term=Eur+Urol+2011%3B59(4)%3A498-505
 
54 - Burkhard F (2006)
Burkhard F, Schumacher M, Studer U. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006;3(9):454-5. [link]
 
55 - Bundschuh R (2013)
Bundschuh R, Wendl C, Weirich G, et al. Tumour volume delineation in prostate cancer assessed by ((11)C)choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 2013;40(6):824-31. [link]
 
56 - Burch P (2000)
Burch P, Breen J, Buckner J, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6(6):2175-82. [link]
 
57 - Burnett A (2007)
Burnett A, Aus G, Canby-Hagino E, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007;178(2):597-601. [link]
 
58 - Burns P (2006)
Burns P, Wilson S. Microbubble contrast for radiological imaging: 1. Principles. Ultrasound Q 2006;22(1):5-13. [link]
 
59 - Burri R (2010)
Burri R, Stone N, Unger P, et al. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;77(5):1338-44. [link]
 
60 - Buyyounouski M (2005)
Buyyounouski M, Hanlon A, Eisenberg D, et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 2005;63:1455-62. [link]
 
61 - Cagiannos I (2003)
Cagiannos I, Karakiewicz P, Eastham J, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170(5):1798-803. [link]
 
62 - Cai T (2011)
Cai T, Nesi G, Tinacci G, et al. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. J Surg Res 2011;167(2):267-72. [link]
 
63 - Caloglu M (2011)
Caloglu M, Ciezki J, Reddy C, et al. PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up. Int J Radiat Oncol Biol Phys 2011;80(3):735-41. [link]
 
64 - Carlsson S (2007)
Carlsson S, Aus G, Wessman C, et al. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study. Eur J Cancer 2007;43(14):2109-16. [link]
 
65 - Casciani E (2004)
Casciani E, Polettini E, Bertini L, et al. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med (Torino) 2004;108(5-6):530-41. [link]
 
66 - Casciani E (2007)
Casciani E, Polettini E, Bertini L, et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007;32(6):796-802. [link]
 
67 - Catalona W (1994)
Catalona W, Richie J, Ahmann F, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283-90. [link]
 
68 - Cellini N (2002)
Cellini N, Morganti A, Mattiucci G, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002;53:595-9. [link]
 
69 - Centemero A (2010)
Centemero A, Rigatti L, Giraudo D, et al. Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study. Eur Urol 2010;57(6):1039-43. [link]
 
70 - Chauhan S (2010)
Chauhan S, Coelho R, Rocco B, et al. Techniques of nerve-sparing and potency outcomes following robot-assisted laparoscopic prostatectomy. Int Braz J Urol 2010;36(3):259-72. [link]
 
71 - Cheng L (2001)
Cheng L, Zincke H, Blute M, et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91(1):66-73. [link]
 
72 - Cheng L (1999)
Cheng L, Slezak J, Bergstralh E, et al. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 1999;86(4):657-63. [link]
 
73 - Cheng L (2012)
Cheng L, Montironi R, Bostwick D, et al. Staging of prostate cancer. Histopathology 2012;60(1):87-117. [link]
 
74 - Cheng L (2000)
Cheng L, Pisansky T, Ramnani D, et al. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol 2000;13(2):113-8. [link]
 
75 - Chi K (2005)
Chi K. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol 2005;23(1):33-7. [link]
 
76 - Choi M (2011)
Choi M, Choi Y, Yoon B, et al. The Clinical Value of Performing an MRI before Prostate Biopsy. Korean J Urol 2011;52(8):572-7. [link]
 
77 - Chokkalingam AP (2003)
Chokkalingam AP, Nyren O, Johansson JE, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 2003;98:1727-34. [link]
 
78 - Chuang A (2007)
Chuang A, Nielsen M, Hernandez D, et al. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol 2007;178(4 Pt 1):1306-10. [link]
 
79 - Chung E (2013)
Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med 2013;10 Suppl 1:102-11. [link]
 
80 - Cirillo S (2008)
Cirillo S, Petracchini M, Della Monica P, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008;63(8):871-9. [link]
 
81 - Coelho R (2010)
Coelho R, Rocco B, Patel M, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 2010;24(12):2003-15. [link]
 
82 - Colleselli D (2011)
Colleselli D, Hennenlotter J, Schilling D, et al. Impact of clinical parameters on the diagnostic accuracy of endorectal coil MRI for the detection of prostate cancer. Urologia Internationalis 2011;86(4):393-8. [link]
 
83 - Colleselli D (2010)
Colleselli D, Schilling D, Lichy M, et al. Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection. Urologia Internationalis 2010;84(4):388-94. [link]
 
84 - Collin S (2008)
Collin S, Metcalfe C, Donovan J, te al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008;102(10):1400-6. [link]
 
85 - Comet-Batlle J (2003)
Comet-Batlle J, Vilanova-Busquets J, Saladie-Roig J, et al. The value of endorectal MRI in the early diagnosis of prostate cancer. Eur Urol 2003;44(2):201-7. [link]
 
86 - Cornud F (2012)
Cornud F, Rouanne M, Beuvon F, et al. Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D'Amico tumor risk criteria? Eur J Radiol 2012;81(4):e591-7. [link]
 
87 - Crawford E (2011)
Crawford E, Tombal B, Miller K, et al. A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer. J Urol 2011;186:889. [link]
 
88 - Cremers R (1989)
Cremers R, Karim-Kos H, Houterman S, et al. Prostate cancer: Trends in incidence, survival and mortality in the Netherlands, 1989-2006. Eur J Cancer 2010;46(11)2077-87. [link]
 
89 - Crook J (2012)
Crook J, O'Callaghan C, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367(10):895-903. [link]
 
90 - D'Amico A (2011)
D'Amico A, Chen M, Crook J, et al. Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol 2011;29(35):4682-7. [link]
 
91 - Davison B (2012)
Davison B, Breckon E. Impact of Health Information-Seeking Behaviour and Personal factors on preferred role in treatment decision making in men with newly diagnosed prostate cancer. Cancer Nurs 2012;35(6):411-8. [link]
 
92 - Dawson N (2000)
Dawson N, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000;88(4):825-34. [link]
 
93 - de Bono J (2011)
de Bono J, Logothetis C, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005. [link]
 
94 - de Bono J (2010)
de Bono J, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54. [link]
 
95 - De Conti P (2007)
De Conti P, Atallah A, Arruda H, et al. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007(4). [link]
 
96 - de Crevoisier R (2005)
de Crevoisier R, Tucker S, Dong L, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005;62(4):965-73. [link]
 
97 - de Jong I (2003)
de Jong I, Pruim J, Elsinga PH, et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44(3):331-5. [link]
 
98 - de la Taille A (2011)
de la Taille A, Irani J, Graefen M, et al. A clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011;185(6):2119-25. [link]
 
99 - Dearnaley D (2009)
Dearnaley D, Mason M, Parmar M, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009;10(9):872-6. [link]
 
100 - Dearnaley D (2007)
Dearnaley D, Sydes M, Graham J, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8(6):475-87. [link]
 
101 - Dearnaley D (2003)
Dearnaley D, Sydes M, Mason M, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95(17):1300-11. [link]
 
102 - Delongchamps N (2011)
Delongchamps N, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011;107(9):1411-8. [link]
 
103 - Denberg T (2006)
Denberg T, Melhado T, Steiner J. Patient treatment preferences in lokalized prostate carcinoma. The influence of emotion, misconception and anecdote. Cancer 2006;107(3):620-30. [link]
 
104 - Deserno W (2011)
Deserno W, Debats O, Rozema T, et al. Comparison of nodal risk formula and MR lymphography for predicting lymph node involvement in prostate cancer. Int J Radiat Oncol Biol Phys 2011;81(1):8-15. [link]
 
105 - Diel I (2007)
Diel I, Fogelman I, Al-Nawas B, et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 2007;64(3):198-207. [link]
 
106 - Divrik R (2007)
Divrik R, Eroglu A, Sahin A, et al. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Urol Oncol 2007;25(5):376-82. [link]
 
107 - Djulbegovic M (2010)
Djulbegovic M, Beyth R, Neuberger M, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543. [link]
 
108 - Draisma G (2003)
Draisma G, Boer R, Otto S, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomised Study of Screening for Prostate Cancer. JNCI 2003:95(12) 868-78. [link]
 
109 - Dupont A (1993)
Dupont A, Gomez J, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150(3):908-13. [link]
 
110 - Dy S (2008)
Dy S, Asch S, Naeim A, et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008;26(23):3879-85. [link]
 
111 - Egevad L (2009)
Egevad L, Algaba F, Berney D, et al. European Network of Uropathology. The European Network of Uropathology: a novel mechanism for communication between pathologists. Anal Quant Cytol Histol 2009;31(2):90-5. [link]
 
112 - Eggener S (2007)
Eggener S, Scardino P, Carroll P, et al. Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and Modalities. J Urol 2007;178(6):2260-7. [link]
 
113 - Eifler J (2006)
Eifler J, Feng Z, Lin B, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 2013;111(1):22-9. [link]
 
114 - Eisenberg M (2008)
Eisenberg M, Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology 2008;72(6):1315-8. [link]
 
115 - Engehausen D (2012)
Engehausen D, Engelhard K, Schwab S, et al. Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer. ScientificWorldJournal 2012:975971. [link]
 
116 - Engelbrecht M (2002)
Engelbrecht M, Jager G, Laheij R, et al. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002;12(9):2294-302. [link]
 
117 - Epstein J (2012)
Epstein J, Feng Z, Trock B, et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012;61(5):1019-24. [link]
 
118 - Etzioni R (2002)
Etzioni R, Penson D, Legler J, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94(13):981-90. [link]
 
119 - Ferro MA (1989)
Ferro MA, Gillatt D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology. 1989;Sep;34(3):134-8.
 
120 - Evangelista L (2013)
Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis. Clin Nucl Med 2013;38(5):305-14. [link]
 
121 - Ficarra V (2012)
Ficarra V, Novara G, Rosen R, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62(3):405-17. [link]
 
122 - Ficarra V (2012)
Ficarra V, Novara G, Ahlering T, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62(3):418-30. [link]
 
123 - Ficarra V (2009)
Ficarra V, Novara G, Fracalanza S, et al. A prospective, non-randomized trial comparing robot-assisted laparoscopic and retropubic radical prostatectomy in one European institution. BJU int 2009;104(4):534-9. [link]
 
124 - Fizazi K (2009)
Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009;182(2):509-15; discussion 15-6. [link]
 
125 - Fizazi K (2011)
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22. [link]
 
126 - Fizazi K (2009)
Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27(10):1564-71. [link]
 
127 - Fleischmann A (2008)
Fleischmann A, Schobinger S, Markwalder R, et al. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology 2008;53(4):468-75. [link]
 
128 - Fowler J (2001)
Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31. [link]
 
129 - Franiel T (2011)
Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology 2011;259(1):162-72. [link]
 
130 - Frankel BM (2007)
Frankel BM, Jones T, Wang C. Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. Neurosurgery 2007;61(3):531-7; discussion 537-8. [link]
 
131 - Freedland S (2004)
Freedland S, Partin A, Epstein J, et al. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 2004;100(8):1646-9. [link]
 
132 - Fuccio C (2011)
Fuccio C, Rubello D, Castellucci P, et al. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 2011 Nov;80(2):e50-6. [link]
 
133 - Fuccio C (2012)
Fuccio C, Castellucci P, Schiavina R, et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 2012;81(8):e893-6. [link]
 
134 - Futterer J (2005)
Futterer J, Engelbrecht M, Huisman H, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005;237(2):541-9. [link]
 
135 - Futterer J (2007)
Futterer J, Engelbrecht M, Jager G, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007;17(4):1055-65. [link]
 
136 - Ganswindt U (2010)
Ganswindt U, Schilling D, Müller A, et al. Distribution of Prostate Sentinel Nodes: A SPECT-Derived Anatomic Atlas. Int J Radiat Oncol Biol Phys 2010;79, 1364-72. [link]
 
137 - Garrett KL (2003)
Garrett KL, McNeal JE, Cohen RJ. Intraoperative lymph node staging of prostate cancer: the case against. ANZ J Surg 2003;73(5):263-6. [link]
 
138 - Gebbia V (1996)
Gebbia V, Testa A, Gebbia N. Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996;73(12):1576-80. [link]
 
139 - Ghavamian R (1999)
Ghavamian R, Blute M, Bergstralh E, et al. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 1999;54(1):105-10. [link]
 
140 - Giusti S (2010)
Giusti S, Caramella D, Fruzzetti, E et al. Peripheral zone prostate cancer. Pre-treatment evaluation with MR and 3D 1H MR spectroscopic imaging: correlation with pathologic findings. Abdom Imaging 2010;35(6):757-63. [link]
 
141 - Gomella L (2011)
Gomella L, Liu X, Trabulsi E, et al. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 2011;18(5):5875-83. [link]
 
142 - Goris Gbenou M (2012)
Goris Gbenou M, Peltier A, Addla S, et al. Localising prostate cancer: Comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy. Urol Int 2012;88(1):12-7. [link]
 
143 - Gosselaar C (2008)
Gosselaar C, Kranse R, Roobol M, et al. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 2008;68:985-93. [link]
 
144 - Gosselaar C (2009)
Gosselaar C, Roobol M, van den Bergh R,et al. Digital rectal examination and the diagnosis of prostate cancer - a study based on 8 years and three screenings within the European Randomised Study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2009:55(1):139-46. [link]
 
145 - Gosselaar C (2008)
Gosselaar C, Roobol M, Roemeling S, et al. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008;54(3):581-8. [link]
 
146 - Graser A (2007)
Graser A, Heuck A, Sommer B, et al. Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. AJR Am J Roentgenol 2007; 188(1):84-90. [link]
 
147 - Greene K (2009)
Greene K, Albertsen P, Babaian R, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182(5):2232-2241. [link]
 
148 - Griebling T (1997)
Griebling T, Ozkutlu D, See W, et al. Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod Pathol 1997;10(8):804-9. [link]
 
149 - Grimm P (2012)
Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012;109. [link]
 
150 - Gwede C (2005)
Gwede C, Pow-Sang J, Seigne J, et al. Treatment Decision-Making Strategies and Influences in Patients with Localized Prostate Carcinoma. Cancer 2005;104(7):1381-90. [link]
 
151 - Haese A (2008)
Haese A, de la Taille A, van Poppel H. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54(5):1081-8. [link]
 
152 - Haffner J (2011)
Haffner J, Lemaitre L, Puech P,et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011;108(8 Pt 2):E171-8. [link]
 
153 - Haider M (2008)
Haider M, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(2):425-30. [link]
 
154 - Haldar S (1997)
Haldar S, Basu A, Croce C. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57(2):229-33. [link]
 
155 - Hambrock T (2012)
Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61(1):177-84. [link]
 
156 - Hambrock T (2010)
Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urology 2010;183(2):520-7. [link]
 
157 - Hameed O (2009)
Hameed O, Humphrey P. Immunohistochemical evaluation of prostate needle biopsies using saved interval sections vs new recut sections from the block: a prospective comparison. Am J Clin Pathol 2009;131(5):683-7. [link]
 
158 - Hamilton W (2004)
Hamilton W, Sharp,D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 2004;54:617-21. [link]
 
159 - Han M (2001)
Han M, Partin A, Pound C, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555-65. [link]
 
160 - Hansen J (2013)
Hansen J, Rink M, Bianchi M, et al. External Validation of the Updated Briganti Nomogram to Predict LymphNode Invasion in Prostate Cancer Patients Undergoing Extended Lymph Node Dissection. Prostate 2013;73(2):211-8.
 
161 - Hara T (2003)
Hara T, Kondo T, Hara T, et al. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003;99(3):474-9. [link]
 
162 - Harisinghani M (2003)
Harisinghani M, Barentsz J, Hahn P, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348(25):2491-9. [link]
 
163 - Harisinghani M (2002)
Harisinghani M, Barentsz J, Hahn P. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol 2002;9 Suppl 2:S312-3. [link]
 
164 - Harisinghani M (2003)
Harisinghani M, Barentsz J, Hahn P, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348(25):2491-9. [link]
 
165 - Harnden P (2007)
Harnden P, Shelley M, Coles B, et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8(5):411-9. [link]
 
166 - Hartsell W (2005)
Hartsell W, Scott C, Bruner D, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97(11):798-804. [link]
 
167 - Haseen F (2010)
Haseen F, Murray L, Cardwell C, et al. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 2010;4(2):128-39. [link]
 
168 - Hedlund P (2011)
Hedlund P, Johansson R, Damber J, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol 2011;45(5):346-53. [link]
 
169 - Heemsbergen W (2007)
Heemsbergen W, Hoogeman M, Witte M, et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 GY versus 78 Gy. Int J Radiat Oncol Biol Phys 2007;67(5):1418-24. [link]
 
170 - Heesakkers R (2008)
Heesakkers R, Hovels A, Jager G, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9(9):850-6. [link]
 
171 - Hegarty J (2010)
Hegarty J, Beirne P, Walsh E, et al. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev 2010;11(11):CD006590. [link]
 
172 - Heidenreich A (2007)
Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007 Jul;52(1):29-37. [link]
 
173 - Heidenreich A (2002)
Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167(4):1681-6. [link]
 
174 - Heidenreich A (2001)
Heidenreich A, Hofmann R, Engelmann U. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001;165(1):136-40. [link]
 
175 - Heidenreich A (2001)
Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001;39(2):121-30. [link]
 
176 - Heijnsdijk E (2012)
Heijnsdijk E, Wever E, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367(7):595-605.N Engl J Med 2012;367(7):595-605. [link]
 
177 - Hinnen K (2011)
Hinnen K, Schaapveld M, van Vulpen M, et al. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol 2011;29(34):4510-5. [link]
 
178 - Hoeks C (2012)
Hoeks C, Schouten M, Bomers J, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62(5):902-9. [link]
 
179 - Hofer M (2006)
Hofer M, Kuefer R, Huang W, et al. Prognostic factors in lymph node-positive prostate cancer. Urology 2006;67(5):1016-21. [link]
 
180 - Hong S (2008)
Hong S, Han B, Chung J, et al. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int 2008;102(9):1092-6. [link]
 
181 - Hoskin P (2012)
Hoskin P, Rojas A, Bownes P, et al. Randomised trial of external beam radiotherapey alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012;103(2):217-22. [link]
 
182 - Hovels A (2008)
Hovels A, Heesakkers R, Adang E, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63(4):387-95. [link]
 
183 - Hoyt K (2008)
Hoyt K, Castaneda B, Zhang M. Tissue elasticity properties as biomarkers for prostate cancer. Cancer Biomark 2008;4(4-5):213-25. [link]
 
184 - Hu R (2009)
Hu R, Dunn T, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69(1):16-22. [link]
 
185 - Huber M (2012)
Huber M, Haynes L, Parker C, et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104(4):273-9. [link]
 
186 - Hugosson J (2004)
Hugosson J, Aus G, Lilja H, et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100(7):1397-405. [link]
 
187 - Hugosson J (2010)
Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11(8):725-32. [link]
 
188 - Hull G (2002)
Hull G, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34. [link]
 
189 - Hussain M (2006)
Hussain M, Tangen C, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984-90. [link]
 
190 - Hussain M (1994)
Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994;12(9):1868-75. [link]
 
191 - Hussain M (2013)
Hussain M, Tangen C, Berry D, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368(14):1314-25. [link]
 
192 - Hwii Ko Y (2011)
Hwii Ko Y, Jae Sung D, Gu Kang S, et al. The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score. Asian J Androl 2011;13(3):487-93. [link]
 
193 - Ibrahiem EI (2012)
Ibrahiem EI, Mohsen T, Nabeeh AM, et al. DWI-MRI: single, informative, and noninvasive technique for prostate cancer diagnosis. ScientificWorldJournal 2012;2012:973450. [link]
 
194 - Ilic D (2011)
Ilic D, O'Connor D, Green S, et al. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011 Mar;107(6):882-91. [link]
 
195 - Iremashvili V (2013)
Iremashvili V, Lokeshwar S, Soloway M, et al. Partial sampling of radical prostatectomy specimens: detection of positive margins and extraprostatic extension. Am J Surg Pathol 2013;37(2):219-25. [link]
 
196 - Iremashvili V (2013)
Iremashvili V, Lokeshwar S, Jorda M, et al. Prognostic implications of partial sampling of radical prostatectomy specimens: comparison of 3 methods. J Urol 2013;190(1):84-90. [link]
 
197 - Isebaert S (2013)
Isebaert S, Van den Bergh L, Haustermans K, et al. Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. J Magn Reson Imaging 2013;37(6):1392-401. [link]
 
198 - Iwazawa J (2011)
Iwazawa J, Mitani T, Sassa S, et al. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol 2011;17(3):243-8. [link]
 
199 - Jacob R (2005)
Jacob R, Hanlon A, Horwitz E, et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005;61(3):695-701.
 
200 - James N (2008)
James N, Sydes M, Clarke N, et al. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. Clin Oncol 2008;20(8):577-81. [link]
 
201 - Jeong I (2010)
Jeong I, Kim J, Cho K, et al. Diffusion-weighted magnetic resonance imaging in patients with unilateral prostate cancer on extended prostate biopsy: predictive accuracy of laterality and implications for hemi-ablative therapy. J Urol 2010;184(5):1963-9. [link]
 
202 - Johns L (2003)
Johns L, Houlston R. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91(9):789-94. [link]
 
203 - Joyce R (1998)
Joyce R, Fenton M, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998;159(1):149-53. [link]
 
204 - Jung D (2008)
Jung D, Lee H, Kim S, et al. Preoperative MR imaging in the evaluation of seminal vesicle invasion in prostate cancer: pattern analysis of seminal vesicle lesions. J Magn Reson Imaging 2008;28(1):144-50. [link]
 
205 - Kakehi Y (2000)
Kakehi Y, Kamoto T, Okuno H, et al. Per-operative frozen section examination of pelvic nodes is unnecessary for the majority of clinically localized prostate cancers in the prostate-specific antigen era. Int J Urol 2000;7(8):281-6. [link]
 
206 - Kantoff P (2010)
Kantoff P, Higano C, Shore N, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 201029;363(5):411-22. [link]
 
207 - Katahira K (2011)
Katahira K, Takahara T, Kwee T, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 2011;21(1):188-96. [link]
 
208 - Kelly W (1993)
Kelly W, Scher H. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149(3):607-9. [link]
 
209 - Kiemeney L (2008)
Kiemeney L, Broeders M, Pelger M, et al. Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer 2008;122(4):871-6. [link]
 
210 - Kim B (2012)
Kim B, Kim T, Kwon T, et al. Comparison of Pelvic Phased-Array versus Endorectal Coil Magnetic Resonance Imaging at 3 Tesla for Local Staging of Prostate Cancer. Yonsei Med J 2012;53(3):550-6. [link]
 
211 - Kim J (2005)
Kim J, Hong S, Choi Y, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005;22(5):639-46. [link]
 
212 - Kim M (2012)
Kim M, Hoffman K, Levy L, et al. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 2012;18(1):1-8. [link]
 
213 - Kitajima K (2010)
Kitajima K, Kaji Y, Fukabori Y, et al. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010;31(3):625-31. [link]
 
214 - Kjellman A (2009)
Kjellman A, Akre O, Norming, U et al. 15-year followup of a population based prostate cancer screening study. J Urol 2009;181(4):1615-21. [link]
 
215 - Klotz L (2008)
Klotz L, Boccon-Gibod L, Shore N, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel group phase III study in prostate cancer patients. BJU Int 2008;102:1531-8. [link]
 
216 - Klotz L (1999)
Klotz L, McNeill I, Fleshner N. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161(1):169-72. [link]
 
217 - Koivisto P (1999)
Koivisto P, Schleutker J, Helin H, et al. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res 1999;5(11):3578-82. [link]
 
218 - Kollmeier M (2005)
Kollmeier M, Stock R, Cesaretti J, et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005;173(3):808-12. [link]
 
219 - König K (2005)
König K, Scheipers U, Pesavento A, et al. Initial experiences with real-time elastography guided biopsies of the prostate. J Urol 2005;174(1):115-7. [link]
 
220 - Kuban D (2011)
Kuban D, Levy L, Cheung M, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011;79(5):1310-7. [link]
 
221 - Kubota Y (2008)
Kubota Y, Kamei S, Nakano M, et al. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer. Int J Urol 2008;15(4):322-6. [link]
 
222 - Kucuk O (2001)
Kucuk O, Fisher E, Moinpour C, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001;58(1):53-8. [link]
 
223 - Kvale R (2009)
Kvale R, Moller B, Wahlqvist R, et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU international 2009;103(12):1647-54. [link]
 
224 - Labanaris A (2010)
Labanaris A, Engelhard K, Zugor V, et al. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 2010;13(1):65-70. [link]
 
225 - Labrie F (1988)
Labrie F, Candas B, Cusan L, Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59(3):311-8.
 
226 - Lane R Jr (1998)
Lane R Jr, Lane C, Mangold K, et al. Needle biopsies of the prostate: what constitutes adequate histologic sampling? Arch Pathol Lab Med 1998;122(9):833-5. [link]
 
227 - Langenhuijsen J (2011)
Langenhuijsen J, Smeenk R, Louwe R, et al. Reduction of treatment volume and radiation doses to surrounding tissues with intraprostatic gold markers in prostate cancer radiotherapy. Clin Genitourin Cancer 2011;9(2):109-14. [link]
 
228 - Langley R (2013)
Langley R, Cafferty F, Alhasso A, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol 2013;14(4):306-16. [link]
 
229 - Langley R (2008)
Langley R, Godsland I, Kynaston H, et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008;102(4):442-5. [link]
 
230 - Lawton C (2007)
Lawton C, DeSilvio M, Roach M 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646-55. [link]
 
231 - Lecouvet F (2012)
Lecouvet F, El Mouedden J, Collette L, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012;62(1):68-75. [link]
 
232 - Lecouvet F (2010)
Lecouvet F, Simon M, Tombal B, et al. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 2010;20(12):2973-82. [link]
 
233 - Li H (2006)
Li H, Sugimura K, Kaji Y, et al. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. Am J Roentgenol 2006;186(3):729-42. [link]
 
234 - Liepe K (2007)
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007;28(8):623-30. [link]
 
235 - Lim H (2009)
Lim H, Kim J, Kim K, Cho K. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study. Radiology 2009;250(1):145-51. [link]
 
236 - Linja M (2001)
Linja M, Savinainen K, Saramäki O, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550-5. [link]
 
237 - Litzenberg D (2006)
Litzenberg D, Balter J, Hadley S, et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2006;65(2):548-53. [link]
 
238 - Locke J (2008)
Locke J, Guns E, Lubik A, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68(15):6407-15. [link]
 
239 - Loeb S (2012)
Loeb S, Heuvel van den S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European Randomised Trial. Eur Urol 2012;61(6):1110-4. [link]
 
240 - Lu-Yao G (2009)
Lu-Yao G, Albertsen P, Moore D, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302(11):1202-9. [link]
 
241 - Magi-Galluzzi C (2011)
Magi-Galluzzi C, Evans A, Delahunt B, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 2011;24(1):26-38. [link]
 
242 - Mahler C (1993)
Mahler C, Verhelst J, Denis L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 1993;71(3 Suppl):1068-73. [link]
 
243 - Makarov D (2000)
Makarov D, Trock B, Humphreys E, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095-101. [link]
 
244 - Manni A (1988)
Manni A, Bartholomew M, Caplan R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988;6(9):1456-66. [link]
 
245 - Mantini G (2011)
Mantini G, Tagliaferri L, Mattiucci GC, et al. Effect of Whole Pelvic Radiotherapy for Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy and Long-Term Androgen Deprivation Therapy. Int J Radiat Oncol Biol Phys 2011;81(5):e721-6. [link]
 
246 - Masterson T (2006)
Masterson T, Bianco F Jr, Vickers A, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175(4):1320-4. [link]
 
247 - McClure T (2012)
McClure T, Margolis D, Reiter R, et al. Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology 2012;262(3):874-83. [link]
 
248 - McLeod D (1993)
McLeod D. Antiandrogenic drugs. Cancer 1993;71(3 Suppl):1046-9. [link]
 
249 - Meijer R (2012)
Meijer R, Nunnink C, Wassenaar A, et al. Standard lymph node dissection for bladder cancer: Significant variability in the number of reported lymph nodes. J Urol 2012;187:446-450. [link]
 
250 - Meng M (2000)
Meng M, Carroll P. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J Urol 2000;164:1235-40. [link]
 
251 - Merrimen J (2010)
Merrimen J, Jones G, Srigley J. Is high grade prostatic intraepithelial neoplasia still a risk factor for adenocarcinoma in the era of extended biopsy sampling? Pathology 2010;42(4):325-9. [link]
 
252 - Merrimen J (2010)
Merrimen J, Jones G, Srigley J. Is high grade prostatic intraepithelial neoplasia still a risk factor for adenocarcinoma in the era of extended biopsy sampling? Pathology 2010;42(4):325-9. [link]
 
253 - Michalski J (2010)
Michalski J, Gay H, Jackson A, et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S123-9. [link]
 
254 - Miller K (2011)
Miller K, Fizazi K, Smith M, et al. Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: A number-needed-to-treat (NNT) analysis. J Urol 2011;1:e262.
 
255 - Mitterberger M (2007)
Mitterberger M, Horninger W, Pelzer A, et al. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection. Prostate 2007;67(14):1537-42. [link]
 
256 - Montgomery R (2008)
Montgomery R, Mostaghel E, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68(11):4447-54. [link]
 
257 - Montironi R (2003)
Montironi R, Kwast van der T, Boccon-Gibod L, et al. Handling and pathology reporting of radical prostatectomy specimens. Eur Urol 2003;44(6):626-36. [link]
 
258 - Moore C (2013)
Moore C, Robertson N, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013;63(1):125-40. [link]
 
259 - Moran B (2006)
Moran B, Braccioforte M, Conterato D. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol 2006;176(4):1376-81. [link]
 
260 - Morgan V (2007)
Morgan V, Kyriazi S, Ashley S, et al. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. Acta Radiol 2007;48(6):695-703. [link]
 
261 - Mottet N (2011)
Mottet N, Bellmunt J, Bolla M, t al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59(4):572-83. [link]
 
262 - Moyer V (2012)
Moyer V, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157(2):120-34. [link]
 
263 - Nakashima J (2004)
Nakashima J, Tanimoto A, Imai Y, et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004;64(1):101-5. [link]
 
264 - Nelson C (2006)
Nelson C. An argument to screen for distress in men diagnosed with early-stage prostate cancer. Nature Clinical Practice Urology 2006;3:586-87. [link]
 
265 - Nepple K (2013)
Nepple K, Rosevear H, Stolpen A, et al. Concordance of preoperative prostate endorectal MRI with subsequent prostatectomy specimen in high-risk prostate cancer patients. Urol Oncol 2013;31(5):601-6. [link]
 
266 - Nguyen P (2007)
Nguyen P, D´Amico A, Lee A, et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure, a systematic review of the literature. Cancer;2007;110:1417-28. [link]
 
267 - Nijkamp J (2008)
Nijkamp J, Pos F, Nuver T, et al. Adaptive radiotherapy for prostate cancer using kilovoltage cone-beam computed tomography: first clinical results. Int J Radiat Oncol Biol Phys 20081;70(1):75-82. [link]
 
268 - Nilsson S (2013)
Nilsson S, Franzén L, Parker C, et al. Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases. Clin Genitourin Cancer 2013;11(1):20-6. [link]
 
269 - Niraula S (2013)
Niraula S, Le L, Tannock I. Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials. J Clin Oncol 2013;31(16):2029-36. [link]
 
270 - Norman G (2008)
Norman G, Dean M, Langley R, et al. Parenteral oestrogen in the treatment of prostate cancer: a systematic review. Br J Cancer 2008;98(4):697-707. [link]
 
271 - Novara G (2012)
Novara G, Ficarra V, Mocellin S, et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol 2012;62(3):382-404. [link]
 
272 - Novara G (2012)
Novara G, Ficarra V, Rosen RC, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol 2012;62(3):431-52. [link]
 
273 - Novara G (2010)
Novara G, Ficarra V, D'Elia C, et al. Preoperative criteria to select patients for bilateral nerve-sparing robotic-assisted radical prostatectomy. J Sex Med 2010;7:839-45. [link]
 
274 - Novara G (2011)
Novara G, Ficarra V, D'Elia C, et al. Trifecta outcomes after robot-assisted laparoscopic radical prostatectomy. BJU Int 2011;107(1):100-4. [link]
 
275 - O’Connor A (2009)
O’Connor A, Bennett C, Stacey D, et al. Decisicion aids for people facing health treatment or screening decision. Cochrane database Syst Review 2009;(3): CD001431. [link]
 
276 - Ochiai A (2008)
Ochiai A, Sotelo T, Troncoso P, et al. Natural history of biochemical progression after radical prostatectomy based on length of a positive margin. Urology 2008;71(2):308-12. [link]
 
277 - Oh W (2004)
Oh W, Kantoff P, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22(18):3705-12. [link]
 
278 - Osborn J (1997)
Osborn J, Smith D, Trump D. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol 1997;20(3):308-10. [link]
 
279 - Pallwein L (2007)
Pallwein L, Mitterberger M, Struve P, et al. Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int 2007;100(1):42-6. [link]
 
280 - Pan C (2002)
Pan C, Kim K, Taylor J, et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:1139-45. [link]
 
281 - Panebianco V (2010)
Panebianco V, Sciarra A, Ciccariello M, et al. Role of magnetic resonance spectroscopic imaging ((1H)MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA). Radiol Med (Torino) 2010;115(8):1314-29. [link]
 
282 - Park B (2007)
Park B, Kim B, Kim C, et al. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr 2007;31(4):534-8. [link]
 
283 - Park B (2011)
Park B, Park J, Park S, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. Am J Roentgenol 2011;197(5):W876-81. [link]
 
284 - Park S (2010)
Park S, Kim J, Kim T, et al. The role of endorectal magnetic resonance imaging in predicting extraprostatic extension and seminal vesicle invasion in clinically localized prostate cancer. Korean J Urol 2010;51(5):308-12. [link]
 
285 - Parkash V (2010)
Parkash V, Bifulco C, Feinn R, et al. To count and how to count, that is the question: interobserver and intraobserver variability among pathologists in lymph node counting. Am J Clin Pathol 2010;134(1):42-9. [link]
 
286 - Parker C (2013)
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23. [link]
 
287 - Parker C (2007)
Parker C, Sydes M, Catton C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007;99(6):1376-9. [link]
 
288 - Partin A (2001)
Partin A, Mangold L, Lamm D, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58(6):843-8. [link]
 
289 - Patchell R (2005)
Patchell R, Tibbs P, Regine W, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005;366(9486):643-8. [link]
 
290 - Peeters S (2006)
Peeters S, Lebesque J, Heemsbergen W, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006;64(4):1151-61. [link]
 
291 - Peinemann F (2011)
Peinemann F, Grouven U, Hemkens L, et al. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev 2011;7(7):CD008871. [link]
 
292 - Perrotte P (1999)
Perrotte P, Litwin M, McGuire E, et al. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999;162(2):398-402. [link]
 
293 - Peters M (2013)
Peters M, Moman M, Poel van der H, et al. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World J Urol 2013;31(2):403-9. [link]
 
294 - Petrylak D (2004)
Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. [link]
 
295 - Pfitzenmaier J (2009)
Pfitzenmaier J, Altwein J. Hormonal therapy in the elderly prostate cancer patient. Dtsch Arztebl Int 2009;106(14):242-7. [link]
 
296 - Phillips TH (1991)
Phillips TH, Thompson IM. Digital rectal examination and carcinoma of the prostate. Urol Clin North Am 1991;18:459-65. [link]
 
297 - Picchio M (2011)
Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011;59(1):51-60. [link]
 
298 - Picchio M (2012)
Picchio M, Spinapolice E, Fallanca F, et al. (11C)Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39(1):13-26. [link]
 
299 - Pieters B (2009)
Pieters B, de Back D, Koning C, et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009;93(2):168-73. [link]
 
300 - Pisters L (2009)
Pisters L, Leibovici D, Blute M, et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182(2):517-25; discussion 525-7. [link]
 
301 - Pollack A (2003)
Pollack A, Horwitz E, Movsas B. Treatment of prostate cancer with regionale lymph node (N1) metastasis. Semin Radiat Oncol 2003;13:121-29. [link]
 
302 - Ploussard G (2014)
Ploussard G, de la Taille A, Moulin M, Comparisons of the perioperative, functional, and oncologic outcomes after robot-assisted versus pure extraperitoneal laparoscopic radical prostatectomy. Eur Urol 2014;65(3):610-9. [link]
 
303 - Pommier P (2007)
Pommier P, Chabaud S, Lagrange J, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25:5366-73. [link]
 
304 - Ponholzer A (2012)
Ponholzer A, Lamche M, Klitsch M, et al. Sentinel lymphadenectomy compared to extended lymphadenectomy in men with prostate cancer undergoing prostatectomy. Anticancer Res 2012;32(3):1033-6. [link]
 
305 - Ponsky L (2002)
Ponsky L, Cherullo E, Starkey R, et al. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002;5(2):132-5. [link]
 
306 - Porpiglia F (2013)
Porpiglia F, Morra I, Lucci Chiarissi M, et al. Randomised controlled trial comparing laparoscopic and robot-assisted radical prostatectomy. Eur Urol 2013;63(4):606-614. [link]
 
307 - Portalez D (2010)
Portalez D, Rollin G, Leandri P, et al. Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur Radiol 2010;20(12):2781-90. [link]
 
308 - Postma R (2006)
Postma R, van Leenders A, Roobol M, et al. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006;50(1):70-5. [link]
 
309 - Poulsen M (2012)
Poulsen M, Bouchelouche K, Høilund-Carlsen F, et al. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 2012;110(11):1666-71.
 
310 - Pucar D (2008)
Pucar D, Sella T, Schoder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008;18:87-97. [link]
 
311 - Puech P (2009)
Puech P, Betrouni N, Makni N, et al. Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results. Int J Comput Assist Radiol Surg 2009;4(1):1-10. [link]
 
312 - Ramsey S (2009)
Ramsey S, Zeliadt S, Arora N, et al. Access to information sources and treatment considerations among men with local stage prostate cancer. Urology 2009;74(3):509-15. [link]
 
313 - Ren J (2009)
Ren J, Huan Y, Wang H, et al. Seminal vesicle invasion in prostate cancer: prediction with combined T2-weighted and diffusion-weighted MR imaging. Eur Radiol 2009;19(10):2481-6. [link]
 
314 - Renard-Penna R (2013)
Renard-Penna R, Roupret M, Comperat E, et al. Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: Results from a prospective study. Urol Oncol 2013;31(4):448-54. [link]
 
315 - CBO (2011)
Richtlijnen osteoporose en fractuurpreventie 2011. http://www.cbo.nl/thema/Richtlijnen/Overzicht-richtlijnen/Bewegingsapparaat/?p=242
 
316 - Richie JP (1993)
Richie JP, Catalona WJ, Ahmann FR et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42:365-74. [link]
 
317 - Roach M 3rd (2010)
Roach M 3rd, Nam J, Gagliardi G, et al. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S130-4. [link]
 
318 - Roach M (2006)
Roach M, 3rd, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74. [link]
 
319 - Roach M 3rd (2003)
Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904-11. [link]
 
320 - Roach M 3rd (1994)
Roach M 3rd, Marquez C, Yuo H, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28,33-7. [link]
 
321 - Robertson C (1996)
Robertson C, Roberson K, Padilla G, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996;88(13):908-17. [link]
 
322 - Rochlitz C (1988)
Rochlitz C, Damon L, Russi M, et al. Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 1988;21(4):319-22. [link]
 
323 - Rodriguez E Jr (2009)
Rodriguez E Jr, Finley D, Skarecky D, et al. Single institution 2-year patient reported validated sexual function outcomes after nerve sparing robot assisted radical prostatectomy. J Urol 2009;181(1):259-63. [link]
 
324 - Roelofzzen E (2012)
Roelofzzen E, Crook J, Monninkhof E, et al. External validation of the treatment nomogram to predict acute urinary retention after (125)I prostate brachytherapy. Brachytherapy 2012;11(4):256-264. [link]
 
325 - Roethke M (2012)
Roethke M, Anastasiadis A, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012;30(2):213-8. [link]
 
326 - Roethke M (2013)
Roethke M, Lichy M, Kniess M, et al. Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol 2013;31(5):1111-6. [link]
 
327 - Roobol M (2005)
Roobol M, Roobol D, Schröder F. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 2005;65(2):343-6. [link]
 
328 - Roobol M (2012)
Roobol M, Schröder F, Hugosson J, et al. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 2012;30(2):149-55. [link]
 
329 - Roobol M (2010)
Roobol M, Steyerberg E, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57(1):79-85. [link]
 
330 - Roobol M (2012)
Roobol M, van Vugt H, Loeb S, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012;61(3):577-83. [link]
 
331 - Rouse P (2011)
Rouse P, Shaw G, Ahmed H, et al. Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urologia Internationalis 2011;87(1):49-53. [link]
 
332 - Ruijter E (1999)
Ruijter E, Kaa van de C, Miller G, et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20(1):22-45. [link]
 
333 - Saad F (2010)
Saad F, Eastham J. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 2010;76(5):1175-81. [link]
 
334 - Saad F (2004)
Saad F, Gleason D, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11):879-82. [link]
 
335 - Saad F (2002)
Saad F, Gleason D, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68. [link]
 
336 - Salonia A (2012)
Salonia A, Burnett AL, Graefen M, et al. Prevention and management of post prostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012;62(2);273-86. [link]
 
337 - Samaratunga H (2011)
Samaratunga H, Montironi R, True L, et al. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 2011;24(1):6-15. [link]
 
338 - Sandblom G (2011)
Sandblom G, Varenhorst E, Rosell J, et al. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342:d1539. [link]
 
339 - Sartor A (2008)
Sartor A, Tangen C, Hussain M, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112(11):2393-400. [link]
 
340 - Sartor O (1994)
Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 1994;86(3):222-7. [link]
 
341 - Sartor O (2009)
Sartor O, Gomella L, Gagnier P, et al. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol 2009;16(5):4806-12. [link]
 
342 - Scattoni V (2007)
Scattoni V, Zlotta A, Montironi R, et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007;52(5):1309-22. [link]
 
343 - Schenk J (2011)
Schenk J, Kristal A, Arnold K, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 2011;173(12):1419-28. [link]
 
344 - Scher H (2012)
Scher H, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97. [link]
 
345 - Scher H (2008)
Scher H, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59. [link]
 
346 - Scher H (1997)
Scher H, Liebertz C, Kelly W, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997;15(8):2928-38. [link]
 
347 - Schiavina R (2008)
Schiavina R, Scattoni V, Castellucci P, et al. 11C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms. Eur Urol 2008;54(2):392-401. [link]
 
348 - Schröder FH (1998)
Schröder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90:1817-23. [link]
 
349 - Schröder F (2008)
Schröder F, Kattan M. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008;54(2):274-90. [link]
 
350 - Schröder FH (2008)
Schröder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53(6):1129-37. [link]
 
351 - Schröder F (2012)
Schröder F, Hugosson J, Roobol M, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366(11):981-90. [link]
 
352 - Schröder F (2009)
Schröder F, Hugosson J, Roobol M, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8. [link]
 
353 - Schwarzenböck S (2012)
Schwarzenböck S, Souvatzoglou M, Krause B. Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer. Theranostics 2012;2(3):318-30. [link]
 
354 - Sciarra A (2010)
Sciarra A, Panebianco V, Ciccariello M, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010;16(6):1875-83. [link]
 
355 - Serpa Neto A (2010)
Serpa Neto A, Tobias-Machado M, Esteves M, et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 2010;10:9. [link]
 
356 - Shikanov S (2008)
Shikanov S, Eng M, Bernstein A, et al. Urinary and sexual quality of life 1 year following robotic assisted laparoscopic radical prostatectomy. J Urol 2008;180(2):663-7. [link]
 
357 - Shore N (2011)
Shore N, Smith M, Jievaltas M, et al. Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain. J Clin Oncol Conference: ASCO Annual Meeting 2011;29(15 SUPPL. 1). [link]
 
358 - Singh P (2009)
Singh P, Nicholson C, Ragavan N, et al. Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience. BMC Urol 2009;9:3. [link]
 
359 - Small E (2004)
Small E, Halabi S, Dawson N, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22(6):1025-33. [link]
 
360 - Small E (2003)
Small E, Smith M, Seaman J, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21(23):4277-84. [link]
 
361 - Smith D (1998)
Smith D, Redman B, Flaherty L, et al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52(2):257-60. [link]
 
362 - Snow S (2007)
Snow S, Panton R, Butler L, et al. Incomplete and Inconsistent information provided to men making decision for treatment of early-stage prostate cancer. Urology 2007;69(5):941-5. [link]
 
363 - Song J (2010)
Song J, Li M, Zagaja G, et al. Intraoperative frozen section assessment of pelvic lymph nodes during radical prostatectomy is of limited value. BJU Int 2010;106(10):1463-7. [link]
 
364 - Souvatzoglou M (2011)
Souvatzoglou M, Weirich G, Schwarzenboeck S, et al. The sensitivity of (11C)choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011;17(11):3751-9. [link]
 
365 - Spiess P (2010)
Spiess P, Katz A, Chin J, et al. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int 2010;106(2):194-8. [link]
 
366 - Stacey D (2011)
Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD001431.
 
367 - Stanbrough M (2006)
Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-25. [link]
 
368 - Stapleton A (1997)
Stapleton A, Timme T, Gousse A, et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997;3(8):1389-97. [link]
 
369 - Steginga S (2004)
Steginga S, Occhipinti S, Gardiner R, et al. Prospective study of men’s psychological and decision-related adjustement after treatment for localized prostate cancer. Urology 2004;63(4):751-6. [link]
 
370 - Stein J (2007)
Stein J, Penson D, Cai J, et al. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol 2007;177(3):876-81; discussion 881-2. [link]
 
371 - Strand C (2010)
Strand C, Aponte S, Chatterjee M, et al. Improved resolution of diagnostic problems in selected prostate needle biopsy specimens by using the ASAP workup: a prospective study of interval sections vs new recut sections. Am J Clin Pathol 2010;134(2):293-8. [link]
 
372 - Stephenson A (2009)
Stephenson A, Kattan M, Eastham J, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27(26):4300-5. [link]
 
373 - Stephenson A (2007)
Stephenson A, Scardino P, Kattan M, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035-41. [link]
 
374 - Studer U (2008)
Studer U, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53(5):941-9. [link]
 
375 - Studer U (2006)
Studer U, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24(12):1868-76. [link]
 
376 - Sumura M (2007)
Sumura M, Shigeno K, Hyuga T, et al. Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study. Int J Urol 2007;14(9):811-6. [link]
 
377 - Taira A (2013)
Taira A, Merrick G, Bennett A, et al. Transperineal Template-guided Mapping Biopsy as a Staging Procedure to Select Patients Best Suited for Active Surveillance. Am J Clin Oncol 2013;36(2):116-20. [link]
 
378 - Tal R (2009)
Tal R, Alphs H, Krebs P, et al. Erectile function recovery rate after radical prostatectomy: A meta-analysis. J Sex Med 2009;6(9):2538-46. [link]
 
379 - Tamada T (2011)
Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. Am J Roentgenol 2011;197(3):664-70. [link]
 
380 - Tan C (2012)
Tan C, Wei W, Johnson V, et al. Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. Am J Roentgenol 2012;199(4):822-9. [link]
 
381 - Tan P (2011)
Tan P, Cheng L, Srigley J,et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol 2011;24(1):48-57. [link]
 
382 - Tanimoto A (2007)
Tanimoto A, Nakashima J, Kohno H, et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25(1):146-52. [link]
 
383 - Tannock I (2004)
Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. [link]
 
384 - Taplin M (2003)
Taplin M, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21(14):2673-8. [link]
 
385 - Taylor C (1993)
Taylor C, Elson P, Trump D. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993;11(11):2167-72. [link]
 
386 - Taylor L (2009)
Taylor L, Canfield S, et al. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009;115(11):2388-99. [link]
 
387 - Testa C (2010)
Testa C, Schiavina R, Lodi R, et al. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed 2010;23(9):1017-26. [link]
 
388 - Tewari A (2012)
Tewari A, Sooriakumaran P, Bloch D, et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 2012;62(1):1-15. [link]
 
389 - Theodorescu D (1997)
Theodorescu D, Broder S, Boyd J, et al. P53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158(1):131-7. [link]
 
390 - Thompson I (2006)
Thompson I, Ankerst D, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98(8):529-34. [link]
 
391 - Thompson I (2004)
Thompson I, Pauler D, Goodman P, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-46. [link]
 
392 - Tokuda Y (2010)
Tokuda Y, Carlino L, Gopalan A, et al. Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol 2010;34(12):1862–7. [link]
 
393 - Touijer K (2007)
Touijer K, Rabbani F, Otero J, et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 2007;178:120–4. [link]
 
394 - Tuncel M (2008)
Tuncel M, Souvatzoglou M, Herrmann K, et al. ((11)C)Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008;35(6):689-95. [link]
 
395 - Tward J (2011)
Tward J, Shrieve D. Correlation of radiotherapy with cause-specific and overall survival in clinically node-positive prostate cancer. J Clin Oncol Conference 2011;29(7 SUPPL. 1). [link]
 
396 - Tward J (2010)
Tward J, Shrieve DC. Radiotherapy is correlated with superior survival in clinically node positive prostate cancer. Int J Radiat Oncol Biol Phys 2010;1):S31. [link]
 
397 - Uddin Ahmed H (2012)
Uddin Ahmed H, Cathcart P, Chalasani V, et al. Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer 2012;118(12):3071-8. [link]
 
398 - Ukimura O (2013)
Ukimura O, Coleman J, Taille de la A, et al. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 2013;63(2):214-30. [link]
 
399 - Umbehr M (2009)
Umbehr M, Bachmann L, Held U, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 2009;55(3):575-90. [link]
 
400 - van den Bergh R (2009)
van den Bergh R, Roemeling S, Roobol M, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55(1):1-8. [link]
 
401 - van der Heide U (2007)
van der Heide U, Kotte A, Dehnad H, et al. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol 2007;82(1):38-45. [link]
 
402 - van der Kwast TH (2006)
van der Kwast TH, Collette L, Van Poppel H, et al. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch 2006;449(4):428-34. [link]
 
403 - Van der Kwast T (2013)
Van der Kwast T, Bubendorf L, Mazerolles C, et al. Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Virchows Arch 2013;463(3):367-77. [link]
 
404 - van der Poel H (2009)
van der Poel H, de Blok W. Role of extent of fascia preservation and erectile function after robot-assisted laparoscopic prostatectomy. Urology 2009;73(4):816-21. [link]
 
405 - van Herk M (1995)
van Herk M, Bruce A, Kroes A, et al. Quantification of organ motion during conformal radiotherapy of the prostate by three dimensional image registration. Int J Radiat Oncol Biol Phys 1995;33(5):1311-20. [link]
 
406 - van Leeuwen P (2010)
van Leeuwen P, Connolly D, Tammela T, et al. Balancing the harms and benefits of early detection of prostate cancer. Cancer 2010;116(20):4857-65. [link]
 
407 - van Oort I (2010)
van Oort I, Bruins H, Kiemeney L, et al. The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy. Histopathology 2010;56(4):464-71. [link]
 
408 - van Oort I (2002)
van Oort I, Witjes J, Kok D, et al. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system. BJU Int 2008;102(4):438-41. [link]
 
409 - van Oort I (2008)
van Oort I, Witjes J, Kok D, et al. Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. World J Urol 2008;26(3):237-41. [link]
 
410 - van Tol-Geerdink J (2013)
van Tol-Geerdink J, Leer J, Weijerman P, et al. Choice between prostatectomy and radiotherapie when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU int 2013;111(4):564-73. [link]
 
411 - van Veggel B (2011)
van Veggel B, van Oort I, Witjes J, et al. Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy. Histopathology 2011;59(4):692-702. [link]
 
412 - van Vugt H (2012)
van Vugt H, Kranse R, Steyerberg E, et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer 2012;48(12):1809-15. [link]
 
413 - van Vugt H (2012)
van Vugt H, Roobol M, Busstra M, et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int 2012;09(10):1480-8. [link]
 
414 - Vargas C (2005)
Vargas C, Galalae R, Demanes J, et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 2005;63:1474-82. [link]
 
415 - Verhagen P (2006)
Verhagen P, van Duijn P, Hermans K, et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006;208(5):699-707. [link]
 
416 - Vesey S (2012)
Vesey S, McCabe J, Hounsome L, et al. UK radical prostatectomy outcomes and surgeo case volume: based on an analysis of the British Association of Urological Surgeons Complex Operation Databse. BJU int 2012;109(3):346-54. [link]
 
417 - Vickers A (2010)
Vickers A, Cronin A, Björk T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521. [link]
 
418 - Vilanova J (2011)
Vilanova J, Barcelo-Vidal C, Comet J, et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. Am J Roentgenol 2011;196(6):W715-22. [link]
 
419 - Villeirs G (2011)
Villeirs G, De Meerleer G, De Visschere P, et al. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 2011;77(2):340-5. [link]
 
420 - Villers A (2006)
Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176:2432-7. [link]
 
421 - Viswanathan A (2010)
Viswanathan A, Yorke E, Marks L, et al. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S116-22. [link]
 
422 - Vogelius I (2010)
Vogelius I, Bentzen S. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer: in regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys 2010;78:11-18). Int J Radiat Oncol Biol Phys 2011;80(1):316; author reply 316-7. [link]
 
423 - Von Bodman C (2010)
Von Bodman C, Godoy G, Chade D, et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol 2010;184(1):143-8. [link]
 
424 - Walz J (2006)
Walz J, Graefen M, Chun F, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006;50(3):498-505. [link]
 
425 - Wang H (2009)
Wang H, Vees H, Miralbell R, et al. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol 2009;93(2):220-5. [link]
 
426 - Wang L (2010)
Wang L, Akin O, Mazaheri Y, et al. Are histopathological features of prostate cancer lesions associated with identification of extracapsular extension on magnetic resonance imaging? BJU Int 2010;106(9):1303-8. [link]
 
427 - Wang L (2006)
Wang L, Hricak H, Kattan M, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. Am J Roentgenol 2006;186(3):743-8. [link]
 
428 - Wang L (2004)
Wang L, Mullerad M, Chen H-N, et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 2004;232(1):133-9. [link]
 
429 - Wang L (2007)
Wang L, Zhang J, Schwartz L, et al.Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol 2007;188(1):99-104. [link]
 
430 - Wang P (2008)
Wang P, Guo Y-m, Liu M, et al. A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean J Radiol 2008;9(5):432-8. [link]
 
431 - Weckermann D (2006)
Weckermann D, Goppelt M, Dorn R, et al. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006;97(6):1173-8. [link]
 
432 - Weinfurt K (2006)
Weinfurt K, Anstrom K, Castel L, et al. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 2006;17(6):986-9. [link]
 
433 - Weingärtner K (1996)
Weingärtner K, Ramaswamy A, Bittinger A, et al. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 1996;156(6):1969-71. [link]
 
434 - Wenske S (2013)
Wenske S, Quarrier S, Katz A. Salvage Cryosurgery of the Prostate for Failure After Primary Radiotherapy or Cryosurgery: Long-term Clinical, Functional, and Oncologic Outcomes in a Large Cohort at a Tertiary Referral Centre. Eur Urol 2013;64(1):1-7. [link]
 
435 - Wiegel T (2009)
Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27(18):2924-30. [link]
 
436 - Wilt T (2012)
Wilt T, Brawer M, Jones K, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203-13. [link]
 
437 - Wilt T (2008)
Wilt T, MacDonald R, Rutks I, et al. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148(6):435-48. [link]
 
438 - Winstanley A (2002)
Winstanley A, Sandison A, Bott S, et al. Incidental findings in pelvic lymph nodes at radical prostatectomy. J Clin Pathol 2002;55(8):623-6. [link]
 
439 - Wu L (2012)
Wu L, Xu J, Ye Y, et al. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. Amer J Roentgenol 2012;199(1):103-10. [link]
 
440 - Wurschmidt F (2011)
Wurschmidt F, Petersen C, Wahl A, et al. (18F)fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 2011;6:44. [link]
 
441 - Yerram N (2012)
Yerram N, Volkin D, Turkbey B, et al. Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU int 2012;110(11):E783-8. [link]
 
442 - Zeegers M (2003)
Zeegers M, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003;97(8):1894-903. [link]
 
443 - Zelefsky M (2012)
Zelefsky M, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;84(1):125-9. [link]
 
444 - Zelefsky M (2001)
Zelefsky M, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166(3):876–81. [link]
 
445 - Zelefsky M (2012)
Zelefsky M, Housman D, Pei X, et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;83(3):953-9.
 
446 - Zelefsky M (2012)
Zelefsky M, Kollmeier M, Cox B, et al. Improved Clinical Outcomes with High-Dose Image Guided Radiotherapy Compared with Non-IGRT for the Treatment of Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2012;84(1):125-9. [link]
 
447 - Zelefsky M (2012)
Zelefsky M, Pei X, Teslova T, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 2012;110(11):1696-701. [link]
 
448 - Zelefsky M (2008)
Zelefsky M, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71(4):1028-33. [link]
 
449 - Zeliadt S (2006)
Zeliadt S, Ramsey S, Penson D, et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate Cancer. Cancer 2006;106(9):1865-74. [link]
 
450 - Zeliadt S (2011)
Zeliadt S, Penson D, Moinpour C, et al. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU int 2011;108(6):851-6. [link]
 
451 - Zhang Z (2003)
Zhang Z, Li M, Wang H, et al. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003;100(20):11636-41. [link]
 
452 - Zhu J (2012)
Zhu J, Wang Y, Xu S, et al. Intermittent androgen blockade or continuous androgen blockade in advanced prostate cancer: a meta-analysis of efficacy, quality of life and side effects. J BUON 2012;17(2):350-6. [link]
 
453 - Zietman A (2010)
Zietman A, Bae K, Slater J, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010;28(7):1106-11. [link]
 
454 - Ouden D van den (2000)
Ouden D van den, Schröder FH. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. World J Urol 2000;18:194-203.
 
455 - Abdel-Khalek M (2004)
Abdel-Khalek M, El-Baz M, Ibrahiem el-H. Is extended 11-core biopsy valuable in benign prostatic hyperplasia patients with intermediate serum prostate-specific antigen (4.1-10 ng/ml) and prior negative sextant biopsy? Scand J Urol Nephrol. 2004;38(4):315-20
 
456 - Abuzallouf S (2004)
Abuzallouf S, Dayes I, Lukkra H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171:2122-7.
 
457 - Adolfsson J (1999)
Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup. J Urol 1999;161:505-8.
 
458 - Albertsen PC (2005)
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
 
459 - Albertsen PC (1998)
Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
 
460 - Albrecht W (2003)
Albrecht W, Collette L, Fava C, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003;44:505-11.
 
461 - Allen EA (1998)
Allen EA, Kahane H, Epstein JL. Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology 1998;52:803-7.
 
462 - Allsbrook WC (2001)
Allsbrook WC, Mangold A, Johnson MH et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Hum Pathol 2001;32:74-80.
 
463 - American Society (1997)
American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys.1997;37:1035-41.
 
464 - Andel G van (1998)
Andel G van, Schlatmann TJM, Karthaus PPM, Heldeweg EH Prostaatkanker. De huidige stand van zaken. Nederl Tijdschr Chroni Ziek, 1998;1:23-6.
 
465 - Andel G (2003)
Andel G. van. Aspects of health related quality of life in prostate cancer. Proefschrift Universiteit van Amsterdam 2003.
 
466 - Anderson (2002)
Anderson phase III randomised trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
 
467 - Arcangeli G (1989)
Arcangeli G, Micheli A, Giannarelli D, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol 1989;14:95-101.
 
468 - Ash D (2000)
Ash D, Flynn A, Battermann JJ, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localised prostate cancer. Radiother Oncol 2000;57:315-21.
 
469 - Augustin H (1999)
Augustin H, Hammerer P, Graefen M, et al. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol 2003;43:113-8.
 
470 - Aus G (2005)
Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51.
 
471 - Aus G (1995)
Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995;154:460-5.
 
472 - Bales GT (1996)
Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(1A Suppl):38-43.
 
473 - Banthia R (2003)
Banthia R, Malcarne VL, Varni JW et al. The effects of dyadic strength and coping styles on psychological distress in couples faced with prostate cancer. J Behav Med 2003;26:31-52.
 
474 - Battermann JJ (2004)
Battermann JJ, Boon TA, Moerland RA, Results of permanent prostate Brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004;71:23-8.
 
475 - Battermann JJ (2000)
Battermann JJ. Feasibility of permanent implant for prostate cancer after previous radiotherapy in the true pelvis. Radiother Oncol 2000;57:297-300.
 
476 - Battermann JJ (2004)
Battermann JJ. Salvage treatment in local relapses after permanent prostate brachytherapy. Radiother Oncol 2004;71 suppl 2:S21.
 
477 - Bauman G (2005)
Bauman G, Charette M, Reid R, Sathya J. Therapeutic Radiopharmaceutical Group of Cancer Care Ontario’s Program in Evidence-based Care. Radiother Oncol 2005;75:258-70.
 
478 - Baxter NN (2005)
Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: A population based study. Gastoenterol 2005;128:819-24.
 
479 - Begg CB (2002)
Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138-44.
 
480 - Bero LA (1998)
Bero LA, Grilli R, Grimshaw JM, Harvey E, er al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998;317:465-8.
 
481 - Beyer DC (2003)
Beyer DC, McKeough T. Impact of prior hormonal therapy on overall and cancer-specific survival following permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys 2003;57 suppl:S176.
 
482 - Beyer DC (2003)
Beyer DC. Brachytherapy for recurrent prostate cancer after radiation therapy. Sem Rad Oncol 2003;13:158-65.
 
483 - Beyersdorff D (2005)
Beyersdorff D, Winkel A, Hamm B, et al. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005;234:576-81.
 
484 - Bill-Axelson A (2005)
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. NEJM 2005;352:1977-84.
 
485 - Bishara T (2004)
Bishara T, Ramnani DM, Epstein JI. High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy. Am J Surg Pathol 2004;28:629-33.
 
486 - Bisson JI (2002)
Bisson JI, Chubb HL, Bennett S et al. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. Brit J Urol 2002;90:56-61.
 
487 - Bjorck JP (1999)
Bjorck JP, Hopp DP, Jones LW. Prostate cancer and emotional functioning: Effects of mental adjustment, optimism, and appraisal. J Psychosocial Oncol 1999;17:71-85.
 
488 - Blanchard CG (1998)
Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Information and decision-making preferences of hospitalized adult cancer patients. Soc Sc & Med 1998;27: 1139-45.
 
489 - Blasko JC (1993)
Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Seminars in Radiation Oncology 1993;3:240-49.
 
490 - Blasko JC (2000)
Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273-8.
 
491 - Blasko JC (2000)
Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-50.
 
492 - Boccon-Gibod L (1997)
Boccon-Gibod L, Fournier G, Bottet P, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997;32:391-5.
 
493 - Bokhour BG (2001)
Bokhour BG, Clark JA, Inui TS et al. Sexuality after treatment for early prostate cancer. Journal of Gen Intern Med 2001;16:649-55.
 
494 - Bolla M (2002)
Bolla M, Colette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103-8.
 
496 - Bolla M (1997)
Bolla M, Gonzalez D, Warde P , et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337: 295-300.
 
497 - Bolla M (2005)
Bolla M, Van Poppel H, Collette L et al, for the European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8.
 
498 - Booker J (2004)
Booker J, Eardley A, Cowan R, et al. Telephone first post-intervention follow-up for men who had radical radiotherapy to the prostat: evaluation of a novel service delivery approach. Eur J Oncol Nurs 2004;8:325-33.
 
499 - Borre M (1997)
Borre M, Nerstrøm B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intend to cure. Cancer 1997;80:917-28.
 
500 - Bostwick DG (2000)
Bostwick DG, Norlen BJ, Denis L. Prostatic intraepithelial neoplasia: the preinvasive stage of prostate cancer. Overview of the prostate committee report. Scand J Urol Nephrol Suppl 2000;205:1-2.
 
501 - Bowers Hayes S (2005)
Bowers Hayes S, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J Clin Ocol 2005;23:8204-11.
 
502 - Boxhall S (2003)
Boxhall S, Dougherty M. An evaluation of a specialist nursing rol for men with prostate cancer, Urologic Nursing 2003;2:148-52.
 
503 - Brachman DG (2000)
Brachman DG, Thomas T, Hilbe J, et al. Failure-free survival following Brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48:111-7.
 
504 - Brenner DJ (2000)
Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406.
 
505 - Bruchovsky N (1990)
Bruchovsky N, Rennie PS, Coldman AJ et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-82.
 
506 - Bubley GJ (1999)
Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-67.
 
507 - Butler L (2001)
Butler L, Downe-Wamboldt B, Marsh S et al. Quality of life post radical prostatectomy: a male perspective. Urolog Nursing 2001;21:283-8.
 
508 - Butow PN (1997)
Butow PN, Maclean M, Dunn SM et al. The dynamics of change: cancer patients' preferences for information, involvement and support. Ann of Oncol 1997;8:857-63.
 
509 - Buyyounouski MK (2005)
Buyyounouski MK, Hanlon AL, Eisenberg DF, et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostae cancer. Int J Radiat Oncol Biol Phys 2005;63:1455-62.
 
510 - Byar DP (1988)
Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-70.
 
511 - Byar DP (1973)
Byar DP. The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973;32:1126-30.
 
512 - Cagiannos (2003)
Cagiannos, Karakiewicz, Eastham, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patient with prostate cancer. J Urol 2003;170:1798-1803.
 
513 - Carlson LE (2001)
Carlson LE, Ottenbreit N, St Pierre M, Bultz BD. Partner understanding of the breast and prostate cancer experience. Cancer Nursing 2001;24:231-9.
 
514 - Carter CA (2003)
Carter CA, Donahue T, Sun L et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 2003;21:4001-8.
 
515 - Carter HB (2002)
Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231-4.
 
516 - Carver CS (1989)
Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol 1989;56:267-83.
 
517 - Cassileth BR (1980)
Cassileth BR, Zupkis RV, Sutton-Smith K, March V. Information and participation preferences among cancer patients. Ann Int Med 1980;92:832-6.
 
518 - Catton C (2003)
Catton C, Milosevic M, Warde P, et al. Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management. In: Theodorecu D (ed.) Follow-up strategies and management of recurrence in urologic oncology. Urol Clin North Am 2003;30:751-63.
 
520 - Chang A (1996)
Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996;14:2250-7.
 
521 - Chang JJ (1998)
Chang JJ, Shinohara K, Bhargava V, Presti JC Jr. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998;160:2111-4.
 
522 - Chaplin BJ (2005)
Chaplin BJ, Wildhagen MF, Schröder FH, et al. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. Eur Urol 2005;48:906-10
 
523 - Cher ML (1998)
Cher ML, Bianco FJ, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-91.
 
524 - Cheville JC (1997)
Cheville JC, Reznicek MJ, Bostwick DG. The focus of “atypical glands, suspicious for malignancy” in prostatic needle biopsy. AM J Clin Pathol 1997;108:633-40.
 
525 - Choo R (2002)
Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664-9.
 
526 - Chybowski FM (1992)
Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J Urol 1992;148:83-86.
 
527 - Ciezki JP (2004)
Ciezki JP, Klein EA, Angermeier K, et al. A retrospective comparison of androgen deprivation (AD) vs no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys 2004;60:1347-50.
 
528 - Collette L (2004)
Collette L, van Andel G, Bottomley A, et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 2004;22:3877-85.
 
529 - Connolly SS (2004)
Connolly SS, O\'Toole GC, O\'Malley KJ, et al. Positive apical surgical margins after radical retropubic prostatectomy, truth or artefact? Scand J Urol Nephrol 2004;38:26-31.
 
530 - Coreil J (1999)
Coreil J, Behal R. Man to man prostate cancer support groups. Cancer Practice 1999;7:122-29.
 
531 - Cornud F (2002)
Cornud F, Flam T, Chauveinc L, et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 2002;224:203-10.
 
532 - Cornud F (2000)
Cornud F, Hamida K, Flam T, et al. Endorectal color doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. Am J Roentgenol 2000;175:1161-8.
 
533 - Cox RL (1995)
Prostate Cancer Trialists\' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
 
534 - Crawford ED (1997)
Crawford ED, Bennett CL,Stone NN. Comparison of perspectives of prostate cancer: analysis of survey data. Urology 1997;50:366-72.
 
535 - Cresswell SM (1995)
Cresswell SM, English PJ, Hall RR,et al. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995;76:360-5.
 
536 - Critz FA (2002)
Critz FA. A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 2002;167:1310-3.
 
537 - Crook J (2000)
Crook J, Malone S, Perry G et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355-67.
 
539 - Cruz M (2002)
Cruz M, Tsuda K, Narumi Y, et al. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol 2002;12:357-65.
 
540 - D’Amico AV (1998)
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 Sep 16;280(11):969-74
 
541 - Da Silva FC (1996)
Da Silva FC, Fossa SD, Aaronson NK et al. The quality of life of patients with newly diagnosed m1 prostate cancer: Experience with EORTC clinical trial 30853. Eur J Cancer 1996;32A:72-7.
 
542 - Davidson PJ (1996)
Davidson PJ, Ouden van den D, Schroeder FH. Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol 1996:29:168-73.
 
543 - Davison BJ (1995)
Davison BJ, Degner LF, Morgan TR. Information and decision-making preferences of men with prostate cancer. Oncol Nurs Forum 1995;22:1401–8.
 
544 - Davison BJ (1997)
Davison BJ, Degner LF. Empowerment of men newly diagnosed with prostate cancer. Cancer Nursing 1997;20:187-96.
 
545 - Davison BJ (2002)
Davison BJ, Gleave ME, Goldenberg SL et al. Assessing information and decision making perferences of men with prostate cancer and their partners. Cancer Nursing 2002;25:42-9.
 
546 - Davison BJ (2003)
Davison BJ, Goldenberg L, Gleave, ME, Degner LF. Provision of individualized information to men and their partners to facilitate treatmens decision making in prostate cancer. Oncology Nursing Forum 2003;30:107
 
547 - Davison BJ (2004)
Davison BJ, Parker PA, Goldenberg SL. Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. Brit J Urol 2004;93:47-51.
 
548 - Davison KP (2000)
Davison KP, Pennebaker JW & Dickerson SS. Who talks? The social psychology of illness support groups. Amer Psychol 2000;55:205-17.
 
549 - Dawson NA (1997)
Dawson NA, McLeod DG. The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur J Cancer 1997;33:560-5.
 
550 - De la Taille A (2000)
De la Taille A, Hayek O, Benson MC, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 2000;55:79-84.
 
551 - De la Taille A (1999)
De la Taille A, Katz A, Bagiella E, et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999;54:1039-43.
 
552 - Dearnaley DP (2003)
Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300-11.
 
553 - Degner LF (1992)
Degner LF, Sloan JA. Decision making during serious illness: What role do patiënts really want to play. Journal of Clinical Epidemiology 1992;45:941-50.
 
554 - Dehnad H (2003)
Dehnad H, Nederveen AJ, van der Heide UA, et al. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol 2003;67-295-302.
 
555 - Denham JW (2005)
Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841-50.
 
556 - Derweesh IH (2004)
Derweesh IH, Kupelian PA, Zippe C, et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004;22:300-6.
 
557 - Desai A (2002)
Desai A, Wu H, Dun L, et al. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. Prostate Cancer Prostatic Disease 2002;5:212-8.
 
558 - Djavan B (1998)
Djavan B, Kadesky K, Klopukh B, et al. Gleasonscores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleasonscores of radical prostatectomy specimens. Eur Urol 1998;33:261-70.
 
559 - Djavan B (2001)
Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166:1679-83.
 
560 - Djavan B (2000)
Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144-9.
 
561 - Dunkel-Schetter C (1992)
Dunkel-Schetter C, Feinstein LG, Taylor SE & Falke RL. Patterns of coping with cancer. Health Psychol 1992;11:79-87.
 
562 - Echlin KN (2002)
Echlin KN, Rees C. Information Needs and Information Behaviors of Men With Prostate Cancer and their Partner: a Review of the Literature. Cancer Nurs 2002;1:35-41.
 
563 - Echlin KN (2002)
Echlin KN, Rees CE. Information needs and information seeking behaviors of men with prostate cancer and their partners: a review of the literature. Cancer Nursing 2002;25:35-41.
 
564 - Edelman MJ (1997)
Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 1997;12:318-31.
 
565 - Edelman S (2000)
Edelman S, Craig A, Kidman AD. Group interventions with cancer patients: efficacy of psychoeducational versus supportie groups. J Psych Oncol 2000:18:67-85.
 
566 - Egan AJ (1997)
Egan AJ, Bostwick DG. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997;21:1496-500.
 
567 - Eichelberger LE (2005)
Eichelberger LE, Koch MO, Eble JN et al. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 2005;18:886-90.
 
568 - Ellison LM (2000)
Ellison LM, Heaney JA, Birkmeyer JD.The effect of hospital volume on mortality and resource use after radical prostatectomy. J Urol 2000;163:867-9.
 
569 - Ellison LM (2005)
Ellison LM, Trock BJ, Poe NR, Partin AW The effect of hospital volume on cancer control after radical prostatectomy. J Urol 2005;173:2094-8.
 
570 - Eng TY (2002)
Eng TY, Thomas CR, Herman TS. Primary radiation therapy for localized prostate cancer. Uro Oncol 2002;7:239-57.
 
571 - Epstein JI (2005)
Epstein JI, Allsbrook WC jr, Amin MB et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9):1228-42.
 
572 - Epstein JI (2006)
Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175:820-34.
 
573 - Epstein JL et al (2004)
Epstein JL et al. Acinar adenocarcinoma. In: WHO Classification of Tumours, Pathology and Genetics, Tumours of the Urinary System and Male Genital Organs, IARC Press, Lyon 2004: 160.
 
574 - Epstein JL (2000)
Epstein JL. Gleasonscore 2-4 adenocarcinoma of the prosate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 2000;24:477-8.
 
575 - Falkmer U (2003)
Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003;42:620-33.
 
576 - Fallowfield LJ (1990)
Fallowfield LJ, Hall A, Maguire GP, Baum M.. Psychological outcomes of different treatment policies in women with early breastcancer outside a clinical trial. Brit Med J 1990; 301:575-80.
 
577 - Farsad M (2005)
Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-9.
 
578 - Feigenberg SJ (2005)
Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int. J. Radiat Oncol Biol Phys. 2005;62:397-405.
 
579 - Feldman JS (1993)
Feldman JS. An alternative group approach: Using multidiscplinary expertise to support patients with prostate cancer and their families. J Psychosocial Oncol 1993;11:83-93.
 
580 - Feldman-Stewart D (2000)
Feldman-Stewart D, Brundage MD et al. What questions do patients with curable prostate cancer want aswered? Med Decision Making 2000; 20:7-19.
 
581 - Feldman-Stewart D (2000)
Feldman-Stewart D, Brundage MD, Hayter C et al. What questions do patiënts with curable prostate cancer want answered? Medical Decision Making 2000;20:7-19.
 
582 - Fellows GJ (1992)
Fellows GJ, Clark PB, Beynon LL, et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. Br J Urol 1992;70:304-9.
 
583 - Fergus KD (2002)
Fergus KD, Gray RE, Fitch MI. Sexual dysfunction and the preservation of manhood: experiences of men with prostate cancer. J Health Psychol 2002;7:303-16.
 
584 - Ferrell BR (1998)
Ferrell BR, Ferrell B The older patient. In J.C.Holland (Ed.), Psycho-oncology 1998 (pp. 839-844). New York: Oxford University Press.
 
585 - Finlay IG (2005)
Finlay IG, Mason MD. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400.
 
586 - Fischer MJ (2006)
Fischer MJ, Visser AP, Voerman AE et al Medical decision making in prostate cancer: patients' participation in complex decisions. Patient Educ aan Couns 2006. In press, 2006
 
587 - Fischer MJ (2006)
Fischer MJ, Visser AP, Voerman AE et al. De medische zorg voor mannen met prostaatkanker in het ziekenhuis. Tijdschr Gezondheidswetensch 2006;84:43-9.
 
588 - Fitch MI (2000)
Fitch MI, Gray R, Franssen E, Johnson B. Men’s perspectives on the impact of prostate cancer: implications for oncology nurses, Oncol Nurs Forum 2000;27:8,1255
 
589 - Fleshner NE (1997)
Fleshner NE, O’Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997;158:505-9.
 
590 - Fobair P (1997)
Fobair P. Cancer support groups and group therapies: Part I. Historical and theoretical background and research on effectiveness. J Psychosocial Oncol 1997;15:63-81.
 
591 - Fosså SD (1989)
Fosså SD, Aaronson NK, da Silva FC et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol 1989;16:335-9.
 
592 - Fossa SD (2001)
Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001;19:62-71.
 
593 - Fowler JE (2002)
Fowler JE, Bigler SA, White PC, Duncan WL. Hormone therapy for locally advanced prostate cancer. J Urol 2002;168:546-9.
 
594 - Fowler JE (1995)
Fowler JE, Braswell NT, Pandey P, Seaver L. Experience with radical prostatectomy and radiation therapy for localised prostate cancer at a Veterans Affair medical center. J Urol 1995;153:1026-31.
 
595 - Fowler JE (1995)
Fowler JE, Brooks J, Pandey P, et al. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153:1011-4.
 
596 - Fowler JE (1981)
Fowler JE, Jr., Whitmore WF, Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372-5.
 
597 - Frauscher F (2002)
Frauscher F, Klauser A, Volgger H, et al. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 2002;167:1648-52.
 
598 - Freedland SJ (2002)
Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleasonscore. J Urol 2002;167:516-20.
 
599 - Freedland SJ (2004)
Freedland SJ, Mangold LA, Epstein JI, Partin AW. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. Urology 2004;63:887-91
 
600 - Fütterer JJ (2005)
Fütterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging Prostate Cancer with Dynamic Contrast-enhanced Endorectal MR Imaging prior to Radical Prostatectomy: Experienced versus Less Experienced Readers. Radiology 2005;237:541-9.
 
601 - Fütterer JJ (2006)
Fütterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer: local staging at 3-T endorectal MR imaging--early experience. Radiology 2006;238:184-91.
 
602 - Gailbraith ME.
Gailbraith ME., Ramiez JM., Pedro LW. Quality of life, health outcomes, and identity for prostate cancer in five different treatmens groups. Oncology Nursing Forum 200;28:552-60.
 
603 - Garnick M.B. (1984)
Garnick M.B., Glode L.M. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 1984;311:1281-6.
 
604 - Garnick MB (1999)
Garnick MB. Hormonal Therapy in the Management of Prostate Cancer: An Historical Overview. Mol Urol 1999;3:175-82.
 
605 - Gheiler E (1998)
Gheiler E, Tefilli M, Tiguert R et al. Predictors for maximal outcome in patients undergoing salvage surgery for radiorecurrent prostate cancer. Urology 1998;51:789-95.
 
606 - Gilligan T (2002)
Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology 2002;60(3 Suppl 1):94-100.
 
607 - Glajchen M (1996)
Glajchen M, Moul JW. Teleconferencing as a method of educating men about managing advanced prostate cancer and pain. J Psychosocial Oncol 1996;14:73-87.
 
608 - Gleason DF (1990)
Gleason DF. Histologic grading in prostatic carcinoma. In: Bostwick DG, ed. Pathology of the prostate. New York: Churchill Livingstone, 1990: 83-93.
 
609 - Gleave M (1998)
Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol 1998;34(Suppl 3):37-41.
 
610 - Gleave ME (2001)
Gleave ME, Goldenberg SL, Chin JL et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 2001;166:500-7.
 
611 - Grado G (1999)
Grado G, Collins J, Kriegshauser J. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10.
 
612 - Gray R (1996)
Gray R, Fitch M, Davis C, Phillips C. Breast cancer and prostate cancer self-help groups: Reflections on differences. Psycho-Oncology 1996;5:137-42.
 
613 - Gray R (2000)
Gray R, Fitch M, Phillips C et al. To tell or not to tell: Patterns of disclosure among men with prostate cancer. Psycho-Oncology 2000:9:273-82.
 
614 - Gray RE (1997)
Gray RE, Fitch M, Davis C, Phillips C. Interviews with men with prostate cancer about their self- help group experience. J Pall Care 1997;13:15-21.
 
615 - Gray RE (1999)
Gray RE, Fitch M, Phillips C et al. Presurgery experiences of prostate cancer patients and their spouses. Cancer Practice 1999;7:130-35.
 
616 - Green R (1999)
Green R, Epstein JL. Use of intervening unstained slides for immunohistochemical stains for high molecular weight cytokeratin on prostate needle biopsy. Am J Surg Pathol 1999;23:567-70.
 
617 - Greer S (1994)
Greer S. Psycho-oncology: its aims, achievements and future tasks. Psycho-Oncology 1994;3,:87-101.
 
618 - Grégoire I (1997)
Grégoire I, Kalogeropoulos D, Corcos J. The effectiveness of a professionally led support group for men with prostate cancer. Urol Nurs 1997;17:58-66.
 
619 - Grimm PD (2001)
Grimm PD, Blasko JC, Sylvester JE, et al. 10 year biochemical (prostate-specific antigen) control op prostate cancer with 125-I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51:31-40.
 
620 - Grise P (2001)
Grise P, Thurman S. Urinary incontinence following treatment of localized prostate cancer. Cancer Contr 2001;8:532-9.
 
621 - Grober ED (2004)
Grober ED, Tsihlias J, Jewett MA, et al. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol 2004;11:2157-62.
 
622 - Grol R (2003)
Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' are. Lancet. 2003;362:1225-30.
 
623 - Gronberg H (1996)
Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nation wide register cohortstudy. Cancer 1996;77:138-43.Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998;82:564-67.
 
624 - Groot MT (2003)
Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-32.
 
625 - Groot V de (2003)
Groot V de, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003;56:221-9.
 
626 - Grossfeld GD (2003)
Grossfeld GD, Latini DM, Lubeck DP et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003;169:157-63.
 
627 - Grossklaus DJ (2002)
Grossklaus DJ, Coffey CS, Shappell SB, et al. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002;167:2032-5
 
628 - Grossklaus DJ (2001)
Grossklaus DJ, Coffey CS, Shappell SB, et al. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int 2001;88:722-6.
 
629 - Guillonneau B (2003)
Guillonneau B, el-Fettouh H, Baumert H, et al. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases at Montsouris Institute. J Urol 2003;169:1261-6.
 
630 - Haapiainen R (1991)
Haapiainen R, Rannikko S, Ruutu M, et al. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer. Br J Urol 1991;67:184-7.
 
631 - Hall JD (2003)
Hall JD, Boyd JC, Lippert MC, Theodorescu D. Why patiënts choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urol 2003;61:402-7.
 
632 - Halpern EJ (2005)
Halpern EJ, Ramey JR, Strup SE, et al. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 2005;104:2373-83.
 
633 - Hamilton W (2004)
Hamilton W, Sharp,D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 2004;54:617-21.Chokkalingam AP, Nyren O, Johansson JE, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 2003;98:1727-34.
 
634 - Han M (2001)
Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year John Hopkins experience. Urol Clin North Am 2001;28:555-65.
 
635 - Hanks GE (2002)
Hanks GE, Hanlon AL, Epstein B, et al. Dose response in prostate cancer with 8-12 years’ follow-up. Int J Radiat Oncol Biol Phys 2002;54:427-35.
 
636 - Hanks GE (1998)
Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five years outcome, treatment optimization, and future direction. Int J Radiat Oncol Biol Phys 1998;41:501-10.
 
637 - Hanks GE (2003)
Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol 2003;21:3972-8.
 
638 - Hanlon AL (2000)
Hanlon AL, Hanks GE. Scrutinity of the ASDTRO consessus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys 2000;46:559-66.
 
639 - Harisinghani MG (2003)
Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
 
640 - Hautmann RE (1994)
Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology 1994;43:47-51.
 
641 - Hedlund PO (2002)
Hedlund PO, Ala-Opas M, Brekkan E, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002;36:405-13.
 
642 - Heesakkers RA (2006)
Heesakkers RA, Futterer JJ, Hovels AM, et al. Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience. Radiology 2006;239:481-7.
 
643 - Heidenreich A (2002)
Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167:1681-6.
 
644 - Heidenreich A (2001)
Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001;39:121-30.
 
645 - Heijmink SW (2006)
Heijmink SW, van Moerkerk H, Kiemeney LA, et al. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol 2006;16:927-38.
 
646 - Heijmink SWTPJ (2006)
Heijmink SWTPJ, Fütterer JJ, Hambrock T, et al. Body array versus endorectal coil MR imaging of prostate cancer at 3 tesla: comparison of image quality, localization, and staging performance with whole-mount section histopathology. Radiology. 2007 Jul;244(1):184-95. Epub 2007 May 10.
 
647 - Heim HM (1993)
Heim HM, Oei TP. Comparison of prostate cancer patients with and without pain. Pain 1993; 53:159-62.
 
648 - Helgason AR (2001)
Helgason AR, Dickman PW, Adolfsson J, Steineck G. Emotional isolation: prevalence and the effect on well-being among 50-80 year old prostate cancer patients. Scand J Urol and Nephrol 2001;35:97-101.
 
649 - Helgesen F (2000)
Helgesen F, Andersson SO, Gustafsson O et al. Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: a randomized study, Scan J Urol Nephrol. 2000;34:55-61.
 
650 - Helgeson VS (1996)
Helgeson VS, Cohen S. Social support and adjustment to cancer: Reconciling descriptive, correlational and intervention research. Health Psychol 1996;15:135-48.
 
651 - Henderson A (2004)
Henderson A, Laing RW, Langley SEM. Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review. Eur Urol 2004;45:134-41.
 
652 - Herr HW (1994)
Herr HW. Quality of life of incontinent men after radical prostatectomy. J Urol, 1994;151:652-4.
 
653 - Hitch PJ (1994)
Hitch PJ, Fielding RG, Llewelyn SP. Effectiveness of self-help and support groups for cancer patients: a review. Psychol and Health 1994;9:437-48.
 
654 - Holmberg L (2002)
Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. NEJM 2002;347:781-9.
 
655 - Horiguchi A (2003)
Horiguchi A, Nakashima J, Horiguchi Y, et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleasonscore in clinically localized prostate cancer. Prostate 2003;56:23-9.
 
656 - Horst van der C (2005)
Horst van der C, Martinez-Portillo FJ, Jünemann KP. Pathofysiologie und Rehabilitation der erektilen Dysfunktion nach nerverhaltender radikaler Prostatektomie. Urologe 2005;44:667-73.
 
657 - Horwitz EM (2001)
Horwitz EM, Winter K, Hanks GE,, et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:947-56.
 
658 - Hoskin PJ (1992)
Hoskin PJ, Price P, Easton D, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992;23:74-8.
 
659 - Hricak H (2004)
Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004;100:2655-63.
 
660 - Hu JC (2003)
Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS.Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21:401-5.
 
661 - Hu JC (2006)
Hu JC, Nelson RA, Wilson TG, Kawachi MH, et al.Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy. J Urol 2006;175:541-6.
 
662 - Huggins C (1941)
Huggins C, Hodges C.V. Studies on prostate cancer I. The effect of castration, of estrogen and of an androgen injection on serum phophatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
 
663 - Hugosson J (1997)
Hugosson J, Aus G. Natural course of localized prostate cancer. A personal view with a review of published papers. Anticancer Res 1997;17:1441-8.
 
664 - Huland H (1994)
Huland H, Hubner D, Henke RP. Systematic biopsies and digital rectal examination to identify the nerve-sparing side for radical prostatectomy without risk of positive margin in patients with clinical stage T2,N0 prostatic carcinoma. Urology 1994;44:211-4.
 
665 - Hull GW (2002)
Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.
 
666 - Hulscher M (2000)
Hulscher M, Wensing M, Grol R. Effectieve implementatie: Theorieën en strategieën. Nijmegen: Werkgroep Onderzoek Kwaliteit, 2000
 
667 - Humphrey PA (2004)
Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17:292-306.
 
668 - Humphrey PA (2003)
Humphrey PA. Grading of prostatic carcinoma. In: Prostate Pathology. ASCP Press: Chicago, 2003:338-74.
 
669 - Hussain M (1994)
Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994;12:1868-75.
 
670 - Iczkowski KA (1998)
Iczkowski KA, Bassler TJ, Schwob VS. Diagnosis of ”suspicious for malignancy” in prostate biopsies. Urology 1998;51:749-58.
 
671 - Incrocci L (2002)
Incrocci L, Slob AK. Incidence, etiology, and therapy for erectile dysfunction after external beam radiotherapy for prostate cancer. Urol 2002;60:1-7.
 
672 - Iversen P (1998)
Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51:389-96.
 
673 - Iversen P (2000)
Iversen P, Tyrrell CJ, Kaisary AV,, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000;164:1579-82.
 
674 - Jacobs JR (2002)
Jacobs JR, Banthia R, Sadler GR, et al. Problems associated with prostate cancer: Differences of opion among health care providers, patiënts and spouses, J Cancer Educ 2002;17:33-6.
 
675 - Jager GJ (1996)
Jager GJ, Barentsz JO, Oosterhof GO, et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma:MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996;167:1503-7.
 
676 - Jager GJ (2000)
Jager GJ, Severens JL, Thornbury JR, et al. Prostate cancer staging: should MR imaging be used? A decision analytic approach. Radiology 2000;215:445-51.
 
677 - Jakobsson L (2001)
Jakobsson L, Loven L, Hallberg IR. Sexual problems in men with prostate cancer in comparison with men with benign prostatic hyperplasia and men from the general population. J Clin Nursing 2001;10:573-82.
 
678 - Jani AB (2003)
Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003;361:1045-53.
 
679 - Johansson JE (1991)
Johansson JE, Andersson SO, Holmberg L, Bergstrom R. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer-a randomized study: results after 7 to 10 years of followup. J Urol 1991;145:519-22.
 
680 - Johansson JE (2004)
Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
 
681 - Johansson JE (1997)
Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer: a prospective, population based study in Sweden. JAMA 1997;277:467-71.
 
682 - Johnson JE (1996)
Johnson JE. Coping with radiation therapy: optimism and the effect of preparatory interventions. Res Nurs Health 1996;19:3-12.
 
683 - Kaisary AV (2001)
Kaisary AV, Iversen P, Tyrrell CJ, et al. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 2001;4:196-203.
 
684 - Kantoff PW (1999)
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13.
 
685 - Kattan MW (2003)
Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792-7.
 
686 - Kattan MW (1999)
Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-1507.
 
687 - Kelsey SG (2004)
Kelsey SG, Owens J, White A. The experience of radiotherapy for localized prostate cancer: the men’s perspective. Eur JCancer Care 2004; 3:272-8.
 
688 - Kim Y (2002)
Kim Y, Roscoe JR, Morrow GR. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. Supp Care Cancer 2002;10:416-21.
 
689 - Klotz L (2005)
Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-9.
 
690 - Kok de E (2004)
Kok de E, Voerman AE, Fischer MJ et al. Het leven gaat door” Prostaatkankerpatiënten en hun partners aan het woord over kwaliteit van leven en psychosociale begeleiding. Utrecht: Helen Dowling Instituut 2004.
 
691 - Kok de E (2005)
Kok de E, Voerman AE, Visser AP, Garssen B.Psychologische problemen van mannen met prostaatkanker. Tijdschr Kanker 2005:29:6-9.
 
692 - Koper PC (2004)
Koper PC, Heemsbergen WD, Hoogeman MS, et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:1072-82.
 
693 - Koper PCM (1999)
Koper PCM, Stroom JC, Putten WLJ van, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999;43:727-34.
 
694 - Kornblith AB (1994)
Kornblith AB, Herr HW, Ofman US et al. Quality of life of patients with prostate cancer and their spouses. Cancer 1994;73:2791-802.
 
695 - Kramer S (1997)
Kramer S, Gorich J, Gottfried HW et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997;70:995-9.
 
696 - Kravchick S (2004)
Kravchick S, Cytron S, Peled R, et al. Optimal combinations for detection of prostate cancer: systematic sextant and laterally directed biopsies versus systematic sextant and color Doppler-targeted biopsies. Urology 2004;63:301-5.
 
697 - Kravchick S (2003)
Kravchick S, Cytron S, Peled R, et al. Using gray-scale and two different techniques of color Doppler sonography to detect prostate cancer. Urology 2003;61:977-81.
 
698 - Krol Y (2000)
Krol Y, Dam van FSAM, Horenblas S et al. Informatiebehoefte van mannen met prostaatkanker en hun partners. Ned Tijdschr voor Geneesk 2000;26:431-7.
 
699 - Krol Y (2000)
Krol Y, Dam van FSAM, Horenblas S, et al. Informatiebehoefte van mannen met prostaatcarcinoom en hun partners, NedTijdschrGeneesk 2000;9:431-6.
 
700 - Kronz JD (2001)
Kronz JD, Allan CH, Shaikh AA, Epstein JL. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25:1079-85.
 
701 - Krupnick JL (1994)
Krupnick JL, Rowland JH, Goldberg RL, Daniel UV. Professionally-led support groups for cancer patients:an intervention in search of a model. Internat J Psychiat Med 1994;23:275-94.
 
702 - Kucway R (2002)
Kucway R, Vicini F, Huang R, et al. Prostate volume reduction with androgen deprivation therapy before interstitial Brachytherapy. J Urol 2002;167:2443-7.
 
703 - Kupelian PA (2004)
Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ?72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.
 
704 - Lavery JF (1999)
Lavery JF, Clarke VA. Prostate cancer. Psychology, Health & Medicine 1999;4:289-302.
 
705 - Lawton CA (2001)
Lawton CA, Winter K, Murray K,, et al. Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
 
706 - Lawton CA (1991)
Lawton CA, Won M, Pilepich MV, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991;21:935-9.
 
707 - Lechevallier E (1999)
Lechevallier E, Eghazarian C, Ortega JC, et al. Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen. Urology.1999;54:857-61.
 
708 - Lee W (1997)
Lee W, Hanks G, Hanlon A. Increasing PSA profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997;15:230-8.
 
709 - Leibel SA (1994)
Leibel SA, Zelefsky MJ, Kutcher GJ, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Sem Oncol 1994;152:1792-8.
 
710 - Lepore SJ (2003)
Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychology, 2003;22:443- 52.
 
711 - Lepore SJ (1998)
Lepore SJ, Helgeson VS. Social constraints, intrusive thoughts, and mental health after prostate cancer. J Soc Clin Psychol 1998;17:89-106.
 
712 - Leventis AK (2001)
Leventis AK, Shariat SF, Kattan MW et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001;19:1030-9.
 
713 - Lim AJ (1995)
Lim AJ, Brandon AH, Fiedler J et al. Quality of life: Radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995;154:1420-5.
 
714 - Litwin MS (1995)
Litwin MS, Hays RD, Fink A et al (1995). Quality-of-life outcoms in men treated for localized prostate cancer. J Am Med Assoc 1995; 273:129-35.
 
715 - Litwin MS (1998)
Litwin MS, Robert JN, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gener Intern Med 1998;13:159-66.
 
716 - Liu M (2005)
Liu M, Pickles T, Berthelet E, et al. Urinary incontinence in prostate cancer patients treated with external beam radiotherapy. Radiother Oncol 2005;74:197-201.
 
717 - Logothetis CJ (1994)
Logothetis CJ, Hoosein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer. Semin Oncol 1994;21:620-9.
 
718 - Luboldt HJ (2003)
Luboldt HJ, Peck KD, Oberpenning F, et al. Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older men. Urology 2003;61:1177-180.
 
719 - Macdonald OK (2004)
Macdonald OK, Schild SE, Vora S et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: Do outcomes differ? Urology. 2004;64:760-4.
 
720 - MacDougal WS (1996)
MacDougal WS. Prostate disease. New York: Random House 1996.
 
721 - Madsen EL (1983)
Madsen EL. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomised trial comparing 4 Gy X 6 versus 10 Gy X 2. Int J Radiat Oncol Biol Phys 1983;9:1775-9.
 
722 - Manni A (1988)
Manni A, Bartholomew M, Caplan R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988;6:1456-66.Aus 2001
 
723 - Massie MJ (1998)
Massie MJ, Popkin MK. Depressive disorders. In J.C.Holland (Ed.), Psycho-oncology 1998 (pp. 518-40). New York: Oxford University Press.
 
724 - Matzkin H (1993)
Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer 1993;72 (Suppl):3788-92.
 
725 - Mazzucchelli R (2002)
Mazzucchelli R, Santinelli A, Lopez-Beltran A, et al. Evaluation of prognostic factors in radical prostatectomy specimens with cancer. Urol Int 2002;68:209-15.
 
726 - McDowell PR (1994)
McDowell PR, Fox WM, Epstein JI. Is submission of remaining tissue necessary when incidental carcinoma of the prostate is found on transurethral resection? Hum Pathol 1994;25:493-7.
 
727 - McLaren DB (1990)
McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1990;82:342-8.
 
728 - McLeod DG (2006)
McLeod DG, Iversen P, See WA, et al. Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247-54.
 
729 - Medical Research Council (1997)
Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the medical research council trial. Br J Urol 1997;79:235-46.
 
730 - Meltzer D (2001)
Meltzer D, Egleston B, Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 2001;91:126-8.
 
731 - Merrick GS (2001)
Merrick GS, Butler WM, Lief JH, et al. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men ? 62 years of age. Int J Radiat Oncol Biol Phys 2001;50:1253-7.
 
732 - Merrick GS (2005)
Merrick GS, Butler WM, Wallace KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61:32-43.
 
733 - Merrick GS (2004)
Merrick GS, Butler WM, Wallner KE, et al. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy. Cancer 2004;10:181-9.
 
734 - Merrick GS (2004)
Merrick GS, Butler WM, Wallner KE, Galbreath RW. Effect of transurethral resection on urinary quality of life after permanent prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2004;58:81-8.
 
735 - Mikkola A (2005)
Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M; Finnprostate group. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 2005;39:294-300.
 
736 - Miyaka H (2004)
Miyaka H, Sakai I, Harada K, et al. Increased detection of clinically significant prostate cancer by additional sampling from the anterior lateral horns of the peripheral zone in combination with the standard sextant biopsy. Int J Urol 2004;11:402-6.
 
737 - Moinpour CM (1998)
Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998;90:1537-44.
 
738 - Montironi R (1996)
Montironi R, Bartels PH, Thompson D et al. Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian belief network. Eur Urol 1996;30:307-15.
 
739 - Moore KN (1995)
Moore KN, Estey A. The early post-operative concerns of men after radical prostatectomy. JAdvNurs 1995;29:1121-9.
 
740 - Mosse CA (2004)
Mosse CA, Magi-Galluzzi C, Tsuzuki T, Epstein J. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 2004;28:394-8.
 
741 - Moyad MA (2005)
Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005 ;66 :1150-4.
 
742 - Mullerad M (2005)
Mullerad M, Hricak H, Kuroiwa K, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer.J Urol 2005;174:2158-63.
 
743 - Murphy GP (1983)
Murphy GP, Beckley S, Brady MF, et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51:1264-72.
 
744 - Murphy GP (1994)
Murphy GP, Mettlin C, Menck H et al. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urology 1994;152:1817-9.
 
745 - Murphy WM (1986)
Murphy WM, Dean PJ, Brasfield JA et al. Incidental carcinoma of the prostate. How much sampling is adequate? Am J Surg Pathol 1986;10:170-4.
 
746 - Nag S (2001)
Nag S, Ciezki JP, Cormack R, et al. Intraoperative planning and evaluation of permanent prostatebrachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2001;51:1422-30.
 
747 - Nakashima J (2004)
Nakashima J, Tanimoto A, Imai Y, et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004;64:101-5.
 
748 - Nelson JB (2003)
Nelson JB, Lepor H. Prostate cancer: radical prostatectomy. In: Theodorecu D, ed. Follow-up strategies and management of recurrence in urologic oncology. Urol Clin North Am 2003;30;703-23.
 
749 - Nesbit RM (1950)
Nesbit RM, Baum WC. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. J Am Med Assoc 1950;143:1317-20.
 
750 - Neulander EZ (2000)
Neulander EZ, Duncan RC, Tiguert R, et al. Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision. BJU 2000;85:699-704.
 
751 - Newell SA (2002)
Newell SA, Sanson-Fisher R, Savolainen NJ. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Nation Canc Instit 2002;94:558-84.
 
752 - Newling D (2001)
Newling D. Advanced prostate cancer: immediate or deferred hormone therapy? Eur Urol 2001;39 Suppl 1:15-21.
 
753 - Nieuwenhuizen C van (1994)
Nieuwenhuizen C van,de Ridder D. Sekseverschillen in omgaan met stress: een overzicht van recente literatuur. Gedrag en Gezondheid 1994;22:55-68.
 
754 - Niewald M (1996)
Niewald M, Tkocz HJ, Abel U et al. Rapid course radiation therapy vs. more standard treatment: a randomised trial for bone metastases. Int J Radiat Oncol Biol Phys 1996;36:1085-9.
 
755 - Niwakawa M (2002)
Niwakawa M, Tobisu K, Fujimoto H, et al. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy. Int J Urol 2002; 9:134-40.
 
756 - Noguchi M (2001)
Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 2001;166:104-9.
 
757 - Norcross-Weintraub F (1990)
Norcross-Weintraub F, Hagopian GA. The effect of nursing consultation on anxiety, side effects and self-care of patient receiving radiation therapy. Oncol Nurs Forum 1990;Suppl3:31-8.
 
758 - Norderhaug I (2003)
Norderhaug I, Dahl O, Høisæter På, et al. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. Eur Urol 2003;44:40-6.
 
759 - Novis DA (1999)
Novis DA, Zarbo RJ, Valenstein PA. Diagnostic uncertainty expressed in prostate needle biopsies. A College of American Pathologists Q-probes study of 15,753 prostate needle biopsy in 332 institutions. Arch Pathol Lab Med 1999;123:687-92.
 
760 - Nygard R (2001)
Nygard R, Norum J, Due J. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res 2001;21:781-8.
 
761 - Obek C (1999)
Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999;161:494-98.
 
762 - Ockrim JL (2003)
Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer--forward to the past? J Urol 2003;169:1735-7.
 
763 - Onur R (2004)
Onur R, Littrup PJ, Pontes JE, Bianco FJ, Jr. Contemporary impact of transrectal ultrasound lesions for prostate cancer detection. J Urol 2004;172:512-4.
 
764 - Ouden D van den (1998)
Ouden D van den, Hop WCJ, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392-7.
 
765 - Ouden D van den (2000)
Ouden D van den, Schröder FH. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. World J Urol 2000;18:194-203.
 
766 - Partin AW (1997)
Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleasonscore to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
 
767 - Partin AW (2001)
Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urol 2001;58:843-8.
 
768 - Passik SD (2003)
Passik SD, Grummon KL. Posttraumatic stress disorder. In J.C.Holland (Ed.), Psycho-oncology.2003 (pp. 595-607). New York: Oxford University Press.
 
769 - Patel MI (2004)
Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004;171:1520-4.
 
770 - Pavone-Macaluso M (1986)
Pavone-Macaluso M, De Voogt HJ, Viggiano G, et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986;136:624-31.
 
771 - Peeters ST (2006)
Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6.
 
772 - Peeters ST (2005)
Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomised trial comparing 68 to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
 
773 - Peeters ST (2005)
Peeters ST, Hoogeman MS, Heemsbergen WD,, et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2005;63: 1142-52.
 
774 - Pelger RC (1998)
Pelger RC, Hamdy NA, Zwinderman AH, et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998;22:403-8.
 
775 - Pelzer A (2005)
Pelzer A, Bektic J, Berger AP, et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005;173:1926-9.
 
776 - Perez MA (2002)
Perez MA, Skinner EC, Meyerowitz BE. Sexuality and intimacy following radical prostatectomy: Patient and partner perspectives. Health Psychol 2002;21: 288-93.
 
777 - Peschel RE (2003)
Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003;4:233-41.
 
778 - Petrylak DP (2004)
Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
 
779 - Phillips TH (1991)
Phillips TH, Thompson IM. Digital rectal examination and carcinoma of the prostate. Urol Clin North Am 1991;18:459-65.
 
780 - Pickles T (1984)
Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol 2002;65:145-51.
 
781 - Pilepich MV (2001)
Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
 
782 - Pilepich (2005)
Pilepich, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma. Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005:61:1285-90.
 
783 - Pinnock C (1998)
Pinnock C, OBrien B., Marshall VR. Older men's concerns about their urological health: a qualitative study. Australian and New Zealand J Public Health 1998;22:368-73.
 
784 - Pirl WF (2002)
Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in man receiving androgen deprevation therapy for prostate c ancer: a pilot study. Psycho-Oncology 2002;11:518-23.
 
785 - Pollack A (2004)
Pollack A, Hanlon AL, Horwitz EM et al. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004;171:1132-6.
 
786 - Pollack A (2003)
Pollack A, Horwitz EM, Movsas B. Treatment of prostate cancer with regionale lymph node (N1) metastasis. Semin Radiat Oncol 2003;13:121-29.
 
787 - Pollack A (2002)
Pollack A, Zagars G, Antolak J et al. prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int.J Radiat Oncol Phys 2002;54.677-85.
 
788 - Pollack A (2002)
Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response:results of the M.D. Anderson phase III randomised trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
 
789 - Poppel H van (2000)
Poppel H van, Goethuys H, Callewaert P, et al. Radical prostatectomy can provide cure for well-selected clinical stage T3 prostate cancer. Eur Urol 2000;38:372-9.
 
790 - Post PN (2001)
Post PN, Hansen BE, Kil PJ, et al. The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. BJU 2001;87:821-6.
 
791 - Potosky AL (2001)
Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-7.
 
792 - Potters L (1999)
Potters L, Cha C, Oshinsky G, Et Al. Risk Profiles To Predict Psa Relapse-Free Survival For Patients Undergoing Permanent Prostate Brachytherapy. Cancer J Sci Am 1999;5:301-6.
 
793 - Potters L (2003)
Potters L. Permanent prostate brachytherapy in men with clinically localised prostate cancer. Clin Oncol 2003;15:301-15.
 
794 - Poulos CK (2004)
Poulos CK, Daggy JK, Cheng L. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Cancer 2004;101:527-32.
 
795 - Presti JC Jr1 (2000)
Presti JC Jr1, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol. 2000 Jan;163(1):163-6; discussion 166-7.
 
796 - Pound CR (1999)
Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
 
797 - Prando A (2000)
Prando A, Wallace S. Helical CT of prostate cancer: early clinical experience. AJR Am J Roentgenol 2000;175:343-6.
 
798 - Prapotnich D (2003)
Prapotnich D, Fizazi K, Escudier B et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43: 233-9.
 
799 - Ptacek JT (1999)
Ptacek JT,.Pierce GR, Ptacek JJ, Nogel C. Stress and coping processes in men with prostate cancer: The divergent views of husbands and wives. J Soc Clinic Psych 1999;18:299-324.
 
800 - Quilty PM (1994)
Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
 
801 - Ragde H (2000)
Ragde H, Korb LJ, Elgamal AA, et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135-41.
 
802 - Raina R (2003)
Raina R, Agarwal A, Goyal KK, et al. Long-term potency after iodine-125 radiotherapy for prostate cancer and the role of sildenafil citrate. Urol 2003;62:1103-8.
 
803 - Rana A. (1994)
Rana A., Chisholm GD, Khan M et al. Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate. Br J Urol 1994;74:637-41.
 
804 - Ravery V (1997)
Ravery V, Boccon-Gibod L. T3 prostate cancer: how reliable is clinical staging? Semin Urol Oncol 1997;15:202-6.
 
805 - Reed D (2003)
Reed D, Wallner K, Merrick G, et al. Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. Urology 2003;62:683-8.
 
806 - Remzi M (2004)
Remzi M, Dobrovits M, Reissigl A, et al. Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy? Eur Urol 2004;46:451-6.
 
807 - Reyes AO (1998)
Reyes AO, Humphrey PA. Diagnostic effect of complete histologic sampling of prostate needle biopsy specimens. Am J Clin Pathol 1998;109:416-22
 
808 - Renshaw AA (1998)
Renshaw AA, Richie JP, Loughlin KR et al. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998;83:748-52.
 
809 - Riemens E (2000)
Riemens E, Visser A.P, van der Jagt T, Vingerhoets A. Psychosociale begeleiding voor mannen met prostaatkanker en hun partners. Evaluatie van een voorlichtingsbijeenkomst en een gespreksgroep. Intern rapport. Rotterdam: Helen Dowling Instituut 2000.
 
810 - Rietbergen JBW (2006)
Rietbergen JBW. Voorkeur voor laparoscopische boven open prostatectomie. Ned Tijdschr Geneeskd 2006;150:138.
 
811 - Ritterband LM (2001)
Ritterband LM, Spielberger CD. Depression in a cancer patient population. J Clinic Psych in Medical Settings 2001, 8, 85-93.
 
812 - Roach 3rd M (2003)
Roach 3rd M. Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol 2003;170:S35-41
 
813 - Robinson JW (2002)
Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-8.
 
814 - Robinson L (1999)
Robinson L, Hughes L, Adler DC, et al. Describing the work of Nursing: The case of postsurgical nursing interventions for men with prostate cancer. Res Nurs Health 1999;22:21–8.
 
815 - Roesch SC (2005)
Roesch SC, Adams L, Hines A et al. Coping with prostate cancer: a meta-analytic review. J Behav Med 2005:28:281-93.
 
816 - Rohr RL (1987)
Rohr RL. Incidental adenocarcinoma in transurethral resections of the prostate. Am J Surg Pathol 1987;11:53-8.
 
817 - Roscigno M (2004)
Roscigno M, Scattoni V, Freschi M,et al. Monofocal and plurifocal high-grade prostatic intraepithelial neoplasia on extended prostate biopsies: factors predicting cancer detection on extended repeat biopsy.Urology 2004;63:1105-10.
 
818 - Rowland JH (1989)
Rowland JH. Developmental stage and adaptation: child and adolecent model. In.Holland JC &.Rowland JH(Eds.), Handbook of psychooncology 1989 (pp. 519-43). New York: Oxford University Press.
 
819 - Ruijter TEG (1996)
Ruijter TEG, Van de Kaa CA, Schalken JA, et al. Histologic Grade Heterogeneity in Multifocal Prostate Cancer: Clinical Implications. J Pathol 1996;180:295-9.
 
820 - Ruijter TEG (1998)
Ruijter TEG, Werahera PN, Van de Kaa CA, et al. Detection of abnormal E-cadherin expression by simulated prostate biopsy. J Urol 1998;160:1368-71.
 
821 - Saad F (2002)
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
 
822 - Sakr WA (1995)
Sakr WA, et al. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995;191:838-41.
 
823 - Sakr WA (1996)
Sakr WA, Wheeler TM, Blute M,et al. Staging and reporting of prostate cancer; sampling of the radical prostatectomy specimen. Cancer 1996;78:366-9.
 
824 - Sala E (2006)
Sala E, Akin O, Moskowitz CS, et al. Endorectal MR Imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology. 2006;238:929-37.
 
825 - Salomon L (1999)
Salomon L, Colombel M, Patard JJ, et al. Value of ultrasound-guided systematic sextant biopsies in prostate tumor mapping. Eur Urol 1999;35:289-93.
 
826 - Samson DJ (2002)
Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95:361-76.
 
827 - Sauvain JL (2003)
Sauvain JL, Palascak P, Bourscheid D, et al. Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. Eur Urol 2003;44:21-30.
 
828 - Schag CA (1994)
Schag CA, Ganz PA, Wing DS et al. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res 1994;3:127-41.
 
829 - Schalken JA (2003)
Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (PCA3)), a highly prostate cancer-specific gene. Urology 2003;62:34-43.
 
830 - Schapira MM (1997)
Schapira MM, Meade C, Nattinger AB. Enhanced decision-making: the use of a videotape decision-aid for patiënts with prostate cancer. Patiënt Educ Couns 1997;30:119-27.
 
831 - Schellhammer PF (1996)
Schellhammer PF. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology 1996;47:622-8.
 
832 - Scher HI (1996)
Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 1996;88:1623-34.
 
833 - Scherr D (2002)
Scherr D, Pitts WR Jr, Vaughn ED Jr. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002;167:535-8.
 
834 - Scherr DS (2003)
Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003;170:1703-8.
 
835 - Schild SE (2001)
Schild SE. Radiation therapy (RT) after prostatectomy: the case for salvage therapy as opposed to adjuvant therapy. Int J Cancer 2001;96:94-8.
 
836 - Schmid DT (2005)
Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-8.
 
837 - Schröder FH (1997)
Schröder FH, Van den Ouden D. Management of locally advanced prostate cancer. 2. Radiotherapy, neoadjuvant endocrine treatment, update 1997-1999. World J Urol 2000;18:204-15.
 
838 - Schröder FH (2004)
Schröder FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the \"European Organization for Research and Treatment of Cancer\" (EORTC) Protocol 30892. Eur Urol 2004;45:457-64.
 
839 - Schulman CC (2000)
Schulman CC, Debruyne FM, Forster G et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol 2000;38:706-13.
 
840 - Scolieri MJ (2000)
Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000;164:1465-72.
 
841 - Shearer RJ (1973)
Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD. Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 1973;45:668-77.
 
842 - Shipley WU (1994)
Shipley WU, Zietman AL, Hanks GE et al. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol 1994;152:1799-805.
 
843 - Singer PA (1991)
Singer PA, Tasch ES, Stocking C. et al. Sex or survival: Trade-offs between Quality and quantity of life. J Clinic Oncol 1991;9:328-34.
 
844 - Small EJ (2000)
Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18:1440-50.
 
845 - Smith DC (1997)
Smith DC. Secondary hormonal therapy. Semin Urol Oncol 1997;15:3-12.
 
846 - Smith Sedhev AE (2001)
Smith Sedhev AE, Pan CC, Epstein JI. Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (Stage T1c) prostatic adenocarcinoma. Hum Pathol 2001;32:494-9.
 
847 - Soerdjbalie-Maikoe V (2002)
Soerdjbalie-Maikoe V, Pelger RC, Nijeholt GA, et al. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging 2002;29:494-8.
 
848 - Soloway MS (2002)
Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen blockade before radical prostatectomy in T2bNXM0 prostate cancer: 5-year results. Lupron depot neoadjuvant prostate study group. J Urol 2002;167:112-6.
 
849 - Spijker van’ t (1980)
Spijker van’ t,A, Trijsburg RW, van Duivenvoorden HJ. Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosomatic Medicine 1997; 59: 280-93.
 
850 - Srigley JR (2000)
Srigley JR, Amin MB, Bostwick DG, et al. for members of the Cancer Committee, College of American Pathologists. Updated protocol for the examination of specimens from patiënts with carcinomas of the prostatic gland. A basis for checklists. Arch Pathol Lab Med 2000;124:1034-9.
 
851 - Stamey TA (1999)
Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-1400.
 
852 - Stanford JL (2000)
Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer. JAMA 2000;283:354-60.
 
853 - Steginga SK (2001)
Steginga SK, Occhipinti S, Dunn J et al. The supportive care needs of men with prostate cancer. Psycho-Oncology 2001;10:66-75.
 
854 - Steginga SK (2004)
Steginga SK, Occhipinti S, Gardiner RA et al. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology 2004;63:751- 6.
 
855 - Steginga SK (2005)
Steginga SK, Pinnock C, Gardner M et al. Evaluating peer support for prostate cancer: the Prostate Cancer Peer Support Inventory. Brit J Urol 2005:95:46-50.
 
856 - Stein SL (1996)
Stein SL, Diamond S, Spiegel D, Morrow GR. Group support in patients with early stage prostate cancer: A URCC CCOP pilot study. Proceedings of the Annual Meeting of the American Sociological and Clinical Oncology 1996;15:A1767
 
857 - Steinberg GD (1998)
Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6.
 
858 - Steineck G (2002)
Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. New England J Medic 2002;347:790-6.
 
859 - Stephenson AJ (2005)
Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol. 2005;23:8198-203.
 
860 - Stephenson AJ (2004)
Stephenson AJ, Shariat SF, Zelefsky MF et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-32.
 
861 - Stewart CS (2001)
Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166:86-91.
 
862 - Stock RG (1997)
Stock RG, Stone NN. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Sem Sur Oncol 1997;13:454-60.
 
863 - Stokes SH (2000)
Stokes SH. Comparison of biochemical diseasefree survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 2000;47:129-36.
 
864 - Stone NN (2002)
Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;427-33.
 
865 - Studer UE (2004)
Studer UE, Hauri D, Hanselmann S et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004;22:4109-18.
 
866 - Studer UE (2006)
Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 2006;24:1868-76.
 
867 - Swanson GP (2002)
Swanson GP, Riggs MW, Earle JD, Haddock MG. Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Europ Urol 2002;42:212-6.
 
868 - Swanson GP (2004)
Swanson GP, Riggs MW, Earle JD. Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:406-11
 
869 - Tannock IF (2004)
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
 
870 - Tannock IF (1996)
Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
 
871 - Tarcan T (1996)
Tarcan T, Turkeri L, Biren T, et al. The effectiveness of imaging modalities in clinical staging of localized prostatic carcinoma. Int Urol Nephrol 1996;28:773-9.
 
872 - Taylor CD (1993)
Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993;11:2167-72.
 
873 - Taylor SE (1983)
Taylor SE. Adjustment to threatening events: a theory of cognitive adaptation. Americ Psychol 1983;38:1161-73.
 
874 - Tefilli MV (1998)
Tefilli MV, Gheiler EL, Tiguert R, et al. Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer. Urology 1998;52:224-9.
 
875 - Telöken C (2001)
Telöken C. Management of erectile dysfunction secondary to treatment for localized prostate cancer. Cancer Contr 2001;8:540-5.
 
876 - Templeton H (2003)
Templeton H, Coates V. Informational needs of men with prostate cancer on hormonal manipulation therapy, Pat EducCouns, 2003;49:243–56.
 
877 - Thomas MD (2000)
Thomas MD, Cormack R, Tempany CM, et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int JRadiat Oncol Biol Phys 2000;47:905-8.
 
878 - Tiguert R (1999)
Tiguert R, Gheiler EL, Tefilli MV, et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 1999;53:367-71.
 
879 - Tinzl M (2004)
Tinzl M, Marberger M, Horvath S, Chypre C. PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-6.
 
880 - Trachtenberg J (1987)
Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 1987;137: 785-8.
 
881 - Tyrrell CJ (1998)
Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of \'Casodex\' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-56.
 
882 - Ukimura O (1997)
Ukimura O, Durrani O, Babaian RJ. Role of PSA and its indices in determining the need for repeat prostate biopsies. Urol 1997;50:66-72.
 
883 - Vaidya A (2000)
Vaidya A, Soloway MS. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. J Urol 2000;164:1998-2001.
 
884 - Valicenti RK (2001)
Valicenti RK, Choi E, Chen C, et al. Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimentional conformal radiation therapy. Urol 2001;57:769-73.
 
885 - Van der Kwast ThH (2003)
Van der Kwast ThH, Lopes C, Santonja C, et al. Guidelines for processing and reporting of prostatic needle biopsy. J Clin Pathol 2003;56:336-40.
 
886 - Van der Linden YM (2004)
Van der Linden YM, Lok JJ, Martijn H, et al. For the Dutch Bone Metastasis Study Group. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004;59:528-37.
 
887 - van Dijck JAA (1989)
van Dijck JAA, Coebergh JWW, Siesling S, Visser O. Trends of cancer in the Netherlands 1989-1998. Utrecht: Vereniging van Integrale Kankercentra, 2002
 
888 - Van Lin EN (2006)
Van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions:gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006;65:291-303
 
889 - Oers (2002)
Van Oers JAM (eindred). Gezondheid op koers? Volksgezondheid Toekomst Verkenning 2002. RIVM rapportnr. 270551001. Houten: Bohn Stafleu Van Loghum, 2002.
 
890 - Vicini FA (1999)
Vicini FA, Kini VR, Spencer W, et al. The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 1999;43:707-13.
 
891 - Vicini Fa (2002)
Vicini Fa, Martinez A, Hanks G, Et Al. An Interinstitutional And Interspecialty Comparison Of Treatment Outcome Data For Patients With Prostate Carcinoma Based On Predefined Prognostic Categories And Minimum Follow-Up. Cancer 2002;95:2126-35.
 
892 - Vicini Fa (2002)
Vicini Fa, Martinez A, Hanks G, Et Al. An Interinstitutional And Interspecialty Comparison Of Treatment Outcome Data For Patients With Prostate Carcinoma Based On Predefined Prognostic Categories And Minimum Follow-Up. Cancer 2002;95:2126-35.
 
893 - Vis AN (2001)
Vis AN, Van der Kwast TH. Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. BJU Int 2001;88:147-57.
 
894 - Visser AP (2000)
Visser AP, van Andel G. Education and counseling in cancer: the neglected case of the prostate cancer patients. Patient Educ Counsel 2000;40:197-9.
 
895 - Visser AP (2003)
Visser AP, van Andel G. Willems P. et al. Changes in health related quality of life of men with prostate cancer 3 month after diagnosis: the role of psychosocial factors and and comparisment with benign prostate hyperplasia patients. Patient Educ Couns 2003;49:225-32.
 
896 - Visser AP (2003)
Visser AP, van Andel G.. Psychosocial and educational aspects in prostate cancer patients. Patient Educ and Couns 2003;49:203-6.
 
897 - Visser GE (1997)
Visser GE, Klinken PC van, Postma-Schuit FCE. Inventarisatie voorlichtings- en ondersteuningsbehoefte van patiënten met prostaatkanker en hun partners. Integraal Kankercentrum Amsterdam, 1997.
 
898 - Voerman AE (2004)
Voerman AE, Fischer MJ, Visser AP et al. Prostaatkanker: een literatuuroverzicht van psychosociale problemen en psychosociale interventies. Gedrag en Gezondheid 2004;32:251-70
 
899 - Voerman AE (2006)
Voerman AE, Fischer MJ, Visser AP et al. Psychosocial problems and need for supportive care in prostate cancer patients. Rapport. Utrecht: Helen Dowling Instituut 2006.
 
900 - Voerman AE (2001)
Voerman AE, Fischer MJ, Visser AP. De kwaliteit van leven, de psychosociale problemen en de behoefte aan begeleiding van mannen met prostaatkanker. Helen Dowling Instituut 2001.
 
901 - VTV (2003)
Volksgezondheid Toekomst Verkenning (VTV), Nationaal Kompas Volksgezondheid. Bilthoven: RIVM, http://www.nationaalkompas.nl> Gezondheid en ziekte\\ Ziekten en aandoeningen\\ Kanker\\Prostaatkanker, 12 mei 2003.
 
902 - Voogt de HJ (1986)
Voogt de HJ, Smith PH, Pavone-Macaluso M, et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303-7.
 
903 - Voogt E (2001)
Voogt E, Visser AP, van.Andel G et al. Behoefte aan begeleiding en sociale steun bij mannen met prostaatkanker Tijdschrift voor Gezondheidswetenschappen 2001;79:378-84.
 
904 - Vugia HD (1991)
Vugia HD. Support groups in oncology: Building hope through the human bond. Journal of Psychosocial Oncology 1991;9:89-108.
 
905 - Wallner KE (1990)
Wallner KE, Nori D, Morse MJ et al. 125-Iodine reimplantation for locally progressive prostatic carcinoma. J Urol 1990;144:704-6.
 
906 - Walsh PC (2000)
Walsh PC, Marschke P, Ricker D, et al. Patient reported incontinence and sexual function following anatomic radical prostatectomy. Urol 2000;55:58.
 
907 - Walsh PC (1997)
Walsh PC, Partin AW. Family history facilitates the early diagnosis of prostate carcinoma Cancer1997;80:1871-74.
 
908 - Wang L (2006)
Wang L, Hricak H, Kattan MW, et al. Prediction of Organ-confined Prostate Cancer: Incremental Value of MR Imaging and MR Spectroscopic Imaging to Staging Nomograms. Radiology 2006;238:597-603.
 
909 - Ward JF (2005)
Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (T3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95:751-6.
 
910 - Waselenko JK (1997)
Waselenko JK, Dawson NA. Management of progressive metastatic prostate cancer. Oncology 1997;11:1551-60.
 
911 - Waymont B (1992)
Waymont B, Lynch TH, Dunn JA, et al. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992;69:614-20.
 
912 - Weber BA (2005)
Weber BA, Navarro P. .Psychosocial consequences of prostate cancer: 30 years of research. Geriatric Nursing 2005;26:166-75.
 
913 - Weber BA (2000)
Weber BA, Roberts BL, McDougall GJ. Exploring the efficacy of support groups for men with prostate cancer. Geriatric Nursing 2000;23:250-3.
 
914 - Wilson NM (2004)
Wilson NM, Masoud AM, Barsoum HB, et al. Correlation of power Doppler with microvessel density in assessing prostate needle biopsy. Clin Radiol 2004;59:946-50.
 
915 - Wilt T (2004)
Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chicester, UK: John Wiley & Sons, Ltd.
 
916 - Winkler MH (2004)
Winkler MH, Khan FA, Kulinskaya E, et al. The total percentage of biopsy cores with cancer improves the prediction of pathological stage after radical prostatectomy. BJU Int 2004;94:812-5.
 
917 - Wirth MP (2004)
Wirth MP, See WA, McLeod DG et al, On behalf of the Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer Program at median followup of 5.4 years. J Urol 2004;172:1865-70.
 
918 - Wirth MP (2004)
Wirth MP, See WA, McLeod DG et al. on behalf of the Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer Program at median followup of 5.4 years. J Urol 2004;172:1865-70.
 
919 - Wirth MP (2004)
Wirth MP, Weissbach L, Marx FJ et al. Prospective randomized trial comparing Flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70.
 
920 - Witjes JA (2006)
Witjes JA. Geen voorkeur voor laparoscopische boven open prostatectomie. NTvG 2006;150:139.
 
921 - Wolf JS (1995)
Wolf JS, Jr., Cher M, Dall\'era M, et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153:993-9.
 
922 - Wolfs GG (1998)
Wolfs GG, Knottnerus JA, van der Horst FG et al. Determinants of doctor consultation for micturition problems in an elderly male population. Europ J Urol 1998;33:1-10.
 
923 - Wong F (2000)
Wong F, Stewart DE, Dancey J et al. Men with prostate cancer: influence of psychological factors on informational needs and decision making. J Psychosom Research 2000;49:13-9.
 
924 - Wu JS (2003)
Wu JS, Wong R, Johnston M, et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594-605.
 
925 - Yock T (2002)
Yock T, Zietman AL, Shipley WU, et al. Long-term durabilkity of PSA failure-free survival after radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:420-6.
 
926 - Yurdakul G (2003)
Yurdakul G, de Reijke TM, Blank LE, Rauws EA. Rectal squamous cell carcinopma 11 years after brachytherapy for carcinoma of the prostate. J Urol 2003;169:280.
 
927 - Zangos S (2005)
Zangos S, Eichler K, Engelmann K, et al. MR-guided transgluteal biopts with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results. Eur Radiol 2005;15:174-82.
 
928 - Zelefsky M (1998)
Zelefsky M, Leibel S, Gaudin P et al. Dose escalation with three-dimensional-conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
 
929 - Zelefsky MJ (2001)
Zelefsky MJ, Fuks Z, Hunt M et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81.
 
930 - Zelefsky MJ (2001)
Zelefsky MJ, Fuks Z, Hunt M. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81.
 
931 - Zelefsky MJ (2003)
Zelefsky MJ, Yamada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;55:956-63.
 
932 - Zietman AL (2004)
Zietman AL, Chung C, Coen CS, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol 2004;171:210-4.
 
933 - Zincke H (2001)
Zincke H, Lau W, Bergstrahl E et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001;166:2208-15.
 
934 - Zincke H (1994)
Zincke H, Oesterling JE, Blute ML, et al. Long term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
 
935 - Afshar-Oromieh A (2014)
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT fort he diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41(1): 11-20. [link]
 
936 - Morigi JJ (2015)
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. Journal of Nuclear Medicine 2015; 56(8): 1185-1190. [link]
 
937 - Akaza H (2009)
Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009 Aug 1;115(15):3437-45. [link]
 
938 - Arai Y (2008)
Arai Y, Akaza H, Deguchi T, Fujisawa M, Hayashi M, Hirao Y, et al. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. Journal of cancer research and clinical oncology. 2008; 134: 1385-96. [link]
 
939 - Baczyk M (2007)
Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun. 2007; 28: 245-50. [link]
 
940 - Bahl A (2013)
Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the tropic trial. Annals of oncology 2013:2402-8.10. [link]
 
941 - Basch E (2013)
Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology. 2013; 14: 1193-99. [link]
 
942 - Beer TM (2014)
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine 2014:424-33. [link]
 
943 - Berthold DR (2008)
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. J Clin Oncol 2008;26(2):242-245. [link]
 
944 - Bilen MA (2015)
Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, et al. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015; 121: 69-76. [link]
 
945 - Bono JS (2010)
Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England) 2010:1147-54. [link]
 
946 - Buchali K (1988)
Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med. 1988; 14: 349-51. [link]
 
947 - Cella D (2015)
Cella D, Ivanescu C, Holmstrom S, Bui CN, Spalding J, Fizazi K. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology. 2015; 26: 179-85. [link]
 
948 - De Bono JS (2011)
De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine. 2011; 364: 1995-2005. [link]
 
949 - Fagerlund A (2015)
Fagerlund A, Cormio L, Palangi L, Lewin R, Santanelli di Pompeo F, Elander A, Selvaggi G. Gynaecomastia in patients with prostate cance: a systematic review. PLoS One 2015;10(8):e0136094. [link]
 
950 - Fizazi K (2015)
Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet Oncology. 2015; 16: 787-94. [link]
 
951 - Fizazi K (2015)
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, Wit R, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Journal of clinical oncology 2015:723-31. [link]
 
952 - Fizazi K (1990)
Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. European journal of cancer (Oxford, England : 1990). 2012; 48: 209-17. [link]
 
953 - Fizazi K (2014)
Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology 2014:1147-56. [link]
 
954 - Fizazi K (2012)
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 2012:983-92. [link]
 
955 - Fossa SD (2001)
Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001;19(1):62-71. [link]
 
956 - Goodman OB (2014)
Goodman OB, Jr., Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases. 2014; 17: 34-9. [link]
 
957 - Gravis G (2015)
Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. European urology. 2015; 68: 196-204. [link]
 
958 - Gravis G (2015)
Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European urology. 2015, 10. [link]
 
959 - Gravis G (2013)
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013; 14: 149-58. [link]
 
960 - Gravis G (1990)
Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, et al. Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). European journal of cancer (Oxford, England : 1990). 2014; 50: 953-62. [link]
 
961 - Han SH (2002)
Han SH, de Klerk JM, Tan S, van het Schip AD, Derksen BH, van Dijk A, et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. Journal of nuclear medicine. 2002; 43: 1150-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=Study.+Journal+of+nuclear+medicine.+2002%3B+43%3A+1150-6
 
962 - Harland S (1990)
Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European journal of cancer (Oxford, England : 1990) 2013:3648-57. [link]
 
963 - Hoskin P (2014)
Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. The Lancet Oncology. 2014; 15: 1397-406. [link]
 
964 - Hussain M (1994)
Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol September 1994, 12(9): 1868-1875. [link]
 
965 - James ND (2015)
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (London, England). 2015, 10. [link]
 
966 - Kantoff PW (2010)
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5): 411-422. [link]
 
967 - Kelly WK (1993)
Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993, 149: 607-609. [link]
 
968 - Lei JH (2016)
Lei JH, Liu LR, Wei Q, Song TR, Yang L, Meng Y, et al. Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis. Asian journal of andrology. 2016; 18. [link]
 
969 - Lewington VJ (1991)
Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991; 27: 954-8. [link]
 
970 - Logothetis CJ (2012)
Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The Lancet Oncology 2012:1210-7. [link]
 
971 - Loriot Y (2015)
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. The Lancet Oncology. 2015; 16: 509-21. [link]
 
972 - Manni A (1988)
Manni A, Bartholomew M, Caplan R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988 Sep, 6(9): 1456-1466. [link]
 
973 - Manni A (1986)
Manni A, Santen RJ, Boucher AE, et al. Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial. Anticancer Res 1986, 6: 309-314. [link]
 
974 - Merseburger AS (2015)
Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, et al. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU international. 2015; 115: 41-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=BJU+international.+2015%3B+115%3A+41-9.
 
975 - Morris MJ (2015)
Morris MJ, Molina A, Small EJ, De Bono JS, Logothetis CJ, Fizazi K, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. Journal of Clinical Oncology. 2015; 33: 1356-63. [link]
 
976 - Mottet N (2016)
Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. European Association of Urology 2016. [link]
 
977 - Mulders PF (2014)
Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. European urology 2014:875-83. [link]
 
978 - Nilsson S (2013)
Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clinical genitourinary cancer. 2013; 11: 20-26. [link]
 
979 - Nilsson S (2007)
Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology. 2007; 8: 587-94. [link]
 
980 - Nome R (2015)
Nome R, Hernes E, Bogsrud TV, Bjoro T, Fossa SD. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scandinavian journal of urology. 2015; 49: 211-7. [link]
 
981 - Oosterhof GO (2003)
Oosterhof GO, Roberts JT, Reijke TM, Engelholm SA, Horenblas S, Maase H, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. European urology 2003:519-26. [link]
 
982 - Parker C (2013)
Parker C, Nilsson DHS, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine. 2013; 369: 213-23. [link]
 
983 - Porter AT (1993)
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993; 25: 805-13. [link]
 
984 - Porter AT (1993)
Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993; 20: 38-43. [link]
 
985 - Rajan P (2015)
Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urologic oncology. 2015; 33: 337. [link]
 
986 - Rathkopf DE (2014)
Rathkopf DE, Smith MR, Bono JS, Logothetis CJ, Shore ND, Souza P, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European urology 2014:815-25. [link]
 
987 - Robinson D (2015)
Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-1228. [link]
 
988 - Roque IFM (2011)
Roque IFM, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011; CD003347. [link]
 
989 - Ryan CJ (2013)
Ryan CJ, Smith MR, Bono JS, Molina A, Logothetis CJ, Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England journal of medicine 2013:138-48. [link]
 
990 - Ryan CJ (2015)
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 2015:152-60. [link]
 
991 - Sartor AO (2008)
Sartor AO, Tangen CM, Hussain MHA, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer. A Southwest Oncology Group Trial (SWOG 9426). Cancer Jun 2008, 112(11): 2393-2400. [link]
 
992 - Sartor O (2014)
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. The Lancet Oncology. 2014; 15: 738-46. [link]
 
993 - Sartor O (2004)
Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004; 63: 940-5. [link]
 
994 - Sartot O (2009)
Sartot O, Gomella GL, Gagnier P, et al. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol 2009, 16(5): 4806-4812. [link]
 
995 - Scher HI (2012)
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012; 367: 1187-97. [link]
 
996 - Sharifi N (2005)
Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238-244. [link]
 
997 - Small EJ (2000)
Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results from a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18(7):1440-1450. [link]
 
998 - Sternberg CN (2014)
Sternberg CN, Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. Annals of Oncology 2014:429-34. [link]
 
999 - Sweeney CJ (2015)
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015; 373: 737-46. [link]
 
1000 - Tannock I (1989)
Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7(5):590-597. [link]
 
1001 - Taylor CD (1993)
Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol November 1993, 11(11): 2167-2172. [link]
 
1002 - Tucci M (2015)
Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, et al. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. European urology. 2015, 10. [link]
 
1003 - Vale CL (2016)
Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016 Feb;17(2):243-56, 10. [link]
 
1004 - Albertsen PC (2014)
Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65: 565-573. [link]
 
1005 - Calais da Silva FE (2009)
Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55(6): 1269-1277. [link]
 
1006 - Cormie P (2015)
Cormie P, Galvao DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU International 2015; 115(2): 256-266. [link]
 
1007 - Crook J (2012)
Crook J, O'Callaghan C, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367(10):895-903. [link]
 
1008 - Gravis G (1990)
Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, et al. Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). European journal of cancer (Oxford, England : 1990). 2014; 50: 953-62. [link]
 
1009 - MRC (1997)
MRC,. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79(2): 235-246. [link]
 
1010 - Salonen AJ (2012)
Salonen AJ, Taari K, Ala-Opas M, et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012; 187(6): 2074-2081. [link]
 
1011 - Ehdale B (2012)

Ehdaie B, Atoria CL, Gupta A et al. Androgen deprivation and thromboembolic events in men with prostate cancer.
Cancer 2012;118(13):3397-406.